BAB 5
SIMPULAN

5.1. Simpulan

Konsentrasi *superdisintegrant* berpengaruh signifikan terhadap sifat mutu fisik tablet. Konsentrasi *superdisintegrant* mempercepat waktu hancur, memperlama waktu pembasahan, dan memperbesar rasio absorpsi air. Sedangkan konsentrasi *superdisintegrant* yang tidak berpengaruh signifikan yaitu kekerasan, kerapuhan tablet, dan %ED. Pada konsentrasi pengikat yang berpengaruh signifikan yaitu memperlama waktu hancur dan memperlama waktu pembasahan. Sedangkan konsentrasi pengikat yang tidak berpengaruh signifikan yaitu kekerasan, kerapuhan, rasio absorpsi air, dan %ED. Interaksi dari konsentrasi *superdisintegrant* dan pengikat tidak berpengaruh signifikan terhadap sifat fisik mutu tablet dan profil pelepasan ODT domperidone secara *in vitro*.

Formula optimum tablet dapat diperoleh dengan konsentrasi *superdisintegrant* 5,075% (Ac-Di-Sol) dan konsentrasi pengikat 0,505% (PVP K-30) dengan hasil teoritis kekerasan tablet 2,93 Kp, kerapuhan tablet 0,82%, waktu hancur 41 detik, waktu pembasahan 59 detik, rasio absorpsi air 47%, dan %ED 79,4%.

5.2. Alur Penelitian Selanjutnya

Perlu dilakukan uji stabilitas dengan waktu pengamatan yang lebih panjang, yaitu tidak kurang dari 3 bulan dan dilakukan penelitian pembuktian beberapa formula optimum terpilih, yang kemudian dibandingkan dengan hasil secara teoritis.

DAFTAR PUSTAKA

Albright, L. M., 2004, Domperidone in Lactation: Use as a Galactogogue, **International Journal of Pharmaceutical Compounding**, 8 (5): 329-335.

Anonim, 1979, **Farmakope Indonesia**, ed. III, Departemen Kesehatan RI, Jakarta, 6-8, 755.

Anonim, 1995, **Farmakope Indonesia**, ed. IV, Departemen Kesehatan RI, Jakarta, 4, 166, 449-450, 488-489, 515, 683, 783-784, 999-1000.

Anonim, 2005, **European Pharmacopeia**, 5th ed., EDQM English, 1473-1475.

Anonim, 2006, **USP29-NF24**, General Information Chapter 1174 Powder Flow, US Pharmacopeial Convention, Rockville, MD, USA.

Anonim, 2007, **US Pharmacopeia XXX**, US Pharmacopeial Convention, Inc., Rockville, 680.

Ansel, C.H, 1989, **Pengantar Bentuk Sediaan Farmasi,** ed. 4, Penerbit Universitas Indonesia, 244 – 245, 251- 259, 271 - 272.

Banakar, U.V., 1992, **Pharmaceutical Disolution Testing**, Marcel Dekker Inc., New York, 19-25.

Bandari, S., Mittapalli, R.K., Gannu, R. and Y.M. Rao, 2008, Orodispersible Tablets: **An Overview**, Asian J. Pharm. 2 (1): 2-11.

Banker, G.S. and N.R. Anderson, 1986, Tablet, in: **The Theory and Practice of Industrial Pharmacy: Tablet**, L. Lachman, H.A. Lieberman, and J.L. Kanig (Eds.), 3rd ed., Lea and Febiger, Philadelphia, 259, 295, 299, 316-329.

Bhowmik, D., Chiranjib.B, Krishnakanth, Pankaj, and R.M. Chandira, 2009, Fast Dissolving Tablet: An Overview, **Journal of Chemical and Pharmaceutical Research**, 1 (1): 163-177

Bolton, S., 1990, **Pharmaceutical Statistics Practical and Clinical Applications**, 2nd ed., Marcel Dekker, Inc., New York, 324-329.

Camarco, W., D. Ray and A. Druffner, 2006, **Selecting Superdisintegrants for Orally Disintegrating Tablet Formulations**, Pharm. Tech. Supplement 28-37.

Deshmukh, V. N., 2012, Mouth Dissolving Drug Delivery System: A Review, **International Journal of PharmTech Research**, 4 (1): 412-421.

Dibbern, H.W., R.M. Muller., E. Wirbitzki, 2002, **UV and IR Spectra**, Editio Cantor Verlag, 579.

Dobetti L., 2001, Fast-Melting tablets: **Development and Technologies. Pharmaceutical technology drug delivery**, 44-50.

Dobetti L., 2003, Fast Disintegrating Tablets, **US Patent** 6, 596, 311.

Duchene, D., 1983, Tablet Disintegration, In: **Topic in Pharmaceutical Science**, P.D. Breimer, and P. Spesier (Eds.), Proceeding of The 43rd International Congreess of Pharmaceutical, Amsterdam, 387-399.

Fiese, E.F. and Hagen, A.T., 1986, Preformulation, In Lachman, L, Lieberman, H.A., and Kanig, J.L., (Eds.): **The Theory and Practice of Industrial Pharmacy**, 3rd Edition, Lea and Febiger, Philadelphia.

Folttmann, H., and Anisul Q., 2008, Polyvinylpyrrolidone (PVP) – One of the Most Widely Used Excipients in Pharmaceuticals: An Overview, **Drug Delivery Technology**, Vol (8) No 6.

Forner, D.E., N.R. Anderson, G.S. Banker, T.W. Rosanske, and R.E. Gordon, 1981, Granulation and Tablet Characteristic, In: **Pharmaceutical Dosage Form**, Lieberman H.A., Lachman L., and J.B. Schwartz, (Eds.), Volume 2, Marcel Dekker,Inc., New York, 109-143, 188-190.

Fu Y, Yang S, Jeong SH, Kimura S, Park K, 2004, Orally fast disintegrating tablets: **Developments, technologies, taste-masking and clinical studies**, Crit Rev Ther Drug Carrier Sys, Vol 21, 433-476.

Ghost, T.K., Chatterjee, D.J., Pfister, W.R., Jarugula, V.R., Fadiran, E.O., Hunt, J.P., Lesko, L.J., Tammara, V.K. and D.B. Hare, 2005, Quick

Dissolving 67 Oral Dosage Forms: Scientific and Regulatory Considerations from A Clinical Pharmacology and Biopharmaceutics Perspective, In: T.K. Ghosh and W.R. Pfister (eds), **Drug Delivery to The Oral Cavity: Molecules to Market**, Boca Raton: Taylor & Francis Group, 344.

Giri,T. K., D. K. Tripathi, and R. Majumdar, 2010, Formulation Aspects In The Development of Orodispersible Tablets: An Overview, **International Journal of Pharmacy and Pharmaceutical Sciences**, 2 (3): 38-42.

Goel, H., Rai, P., Rana, V. and A.K. Tiwary, 2008, Orally Disintegrating Systems: **Innovations in Formulation and Technology**, Recent Pat. Drug Deliv. Formul., 2 (3): 258-274

Goel, H., N. Vora, A. K. Tiwary, V. Rana, 2009, Formulation of Orodispersible Tablets of Ondansentron HCl: Investigation Using Glycine-Chitosan Mixture as Superdisintegrant, **Yakugaku Zasshi**, 129 (5): 513-521.

Gohel, M. C. *and* P. D. Jogani, 2005, A Review Of Co-Processed Directly Compressible Excipients, **J. Pharm. Pharmaceut. Sci.**, 8 (1): 76-93.

Guleria, R., N. S. Kaith, R. Singh, 2011, Improved Dissolution of Domperidone in Solid Dispersion with Polymeric Hydrophillic Additive, **J. Chem. Pharm. Res.**, 3(6):655-664.

Hsu, A.F. and C-H Han, 2005, Oral Disintegrating Dosage Form, **US Patent Application Publication Number 20050147670A1**.

Khan, K.A., 1975, **The Concept of Dissolution Efficiency**. **J. Pharm**, 27 (1), 48-49.

Koseki, T., Onishi, H., Takahashi, Y., Uchida, M. and Y. Machida, 2008, **Development of Novel Fast-Disintegrating Tablets by Direct Compression Using Sucrose Stearic Acid Esters as A Disintegration-Accelerating Agent**. Chem. Pharm. Bull., 56 (10): 1384-1388.

Kumar, M.V., Sethi, P., Kheri, R., Saraogi, G.K., Singhai, A.K., 2011, Orally Disintegrating Tablets: A Review, **International Research Journal of Pharmacy**, 2 (4), 16-22.

Kundu, S. and P.K. Sahoo, 2008, **Recent Trends in The Developments of Orally Disintegrating Tablet Technology**, Pharma Times 40 (4): 11-21.

Lachman, L., H.A. Leiberman, and J.L. Kanig, 1986, **The Theory and Practice of Industrial Pharmacy**, 3rd Edition, Lea and Febiger, Philadelphia, 564-588.

Langenbucher, F., 1972, Linearization of Dissolution Rate Curve by Weibull Distribution, **Journal of Pharmaceutical Sciences**, 24, 979-981.

Lucas, T. I., R. H. Bishara, R. H. Seevers, 2004, A Stability Program for the Distribution of Drug Products, **Pharmaceutical Technology**, 7: 68-73.

Manivannan, R., 2009, Oral Disintegrating Tablets: A Future Compaction, **International Journal of Pharmaceutical Research and Development**, 1 (10): 1-10.

Martin, A., J. Swarbrick, and A. Cammarata, 1993, **Farmasi Fisik: Dasar-dasar Kimia Fisika dalam Ilmu Farmasetik**, vol. 2, ed. 3, terjemahan Yoshita, Universitas Indonesia, Jakarta, 1135.

Parashar, B. *and* A. Chauhan, 2012, Formulation And Evaluation of Fast Disintegrating Tablets of Domperidone, **International Journal of Institutional Pharmacy and Life Sciences**, 2 (3): 232-238.

Parmar R.B., Baria A.H., Tank H.M., Faldu S.D, 2009, Formulation and Evaluation of Domperidone Fast Dissolving Tablets, **International Journal of PharmTech Research**, Vol 1, No 3, 483-487.

Parrott, E.L., 1971, **Pharmaceutical Technology Fundamental Pharmaceutics**, 3rd ed., Burgess Publishing Company, Minneapolis, 17-19, 82, 160-162.

Prajapati, B.G. and D.V. Patel, 2010, Comparative Study of Efficiency of Different Superdisintegrant for Fast Dissolve Tablet of Domperidone, **Journal of Pharmacy Research**, 3(1): 151-155.

Rao, N.G.R., Patel, T. and S. Gandhi, 2009, **Development and Evaluation of Carbamazepine Fast Dissolving Tablets Prepared with A Complex by Direct Compression Technique**, *Asian J. Pharma,* April-June, 3 (2): 97-103.

Rowe, R.C., P.J. Shekey, M.E. Quinn, 2009, **Handbook of Pharmaceutical Excipients**, 6th ed, The Pharmaceutical Press, London, 206-207, 364-368, 404-406, 424-427, 728-730.

Shargel, L. and A.B.C. Yu, 1999, **Applied Biopharmaceutics and Pharmacokinetics,** 4th ed McGraw-Hill. New York, 8, 132, 169-200.

Sharma, K., Pfister, W.R. and T.K. Ghosh, 2005, Quick-Dispersing Oral Drug Delivery Systems, In: T.K. Ghosh and W.R. Pfister (eds), **Drug Delivery to The Oral Cavity: Molecules to Market,** Boca Raton: Taylor & Francis Group, 262-263.

Sharma, S and P. K. Suresh, 2010, Formulation, In Vitro Characterization and Stability Studies of Self Microemulsifying Drug Delivery Systems of Domperidone, **International Journal of Innovative Pharmaceutical Research**, 1 (4): 66-73.

Shervingon, L.A. and A. Shervington, 1998, Guaifenesin, In: **Analytical Profiles of Drug Substances and Excipients**, H.G. Brittain (Ed.), Vol 25, Academic Press, London, 152.

Shukla, D., Chakraborty, S., Singh, S. and B. Mishra, 2009, Mouth Dissolving Tablets I: **An Overview of Formulation Technology**, *J. Sci. Pharm*, 76: 309-326.

Singh, S. K., D. N. Mishra, R. Jassal, P. Soni, 2009, Fast Disintegrating Combination Tablets Of Omeprazole And Domperidone, **Asian Journal of Pharmaceutical and Clinical Research**, 2 (3): 74-82.

Siregar, Ch. J. P., 1992, **Proses validasi and Manufaktur Sediaan tablet**, In : Asyarie S., U. Mar'u, S. Badruzzaman (Eds), Prosiding Seminar Validasi di Industri Farmasi, Jurusan Farmasi FMIPA ITB, Bandung, 26-41.

Sweetman, S.C., 2009, **Martindale The Complete Drug Reference**, 36th ed, Pharmaceutical Press, London, 1726-1727.

Thatipamula R.P., Palem C.R., Gannu R., Mudragada S., Yamsani M.R., 2011, Formulation and In Vitro Characterization of Domperidone Loaded Solid Lipid Nanoparticles and Nanostructured Lipid Carriers, **Daru**, Vol 19, No 1.

Wagner, J.G., 1971, **Biopharmaceutics and Relevant Pharmacokinetics**, 1st ed., Drug Intelligence Publications, Illinois, 64-110.

Yadav, V., Bharat P., Brajesh M., Love S., 2012, Fast Dissolving Tablet, **International Journal of Apllied Pharmaceutics**, Vol 4 (2), 17-22

Zainuddin, M., 2000, **Validasi Metode Analisis Kuantitatif Secara Spektrofotometris Ultra Ungu-Sinar Tampak (UV-Vis)**, Universitas Airlangga, Surabaya.

LAMPIRAN A

HASIL UJI MUTU FISIK GRANUL

Mutu fisik yang diuji	Replikasi	Formula ODT Domperidone				Syarat
		F1	F2	F3	F4	
Kelembapan (%)	I	2,56	4,07	3,04	3,45	2-5% (Ansel, 1989)
	II	3,2	3,72	2,89	3,31	
	III	3,15	3,6	3,18	3,64	
	Rata-rata	2,97	3,80	3,04	3,47	
	SD	0,36	0,24	0,15	0,17	
Hausner Ratio	I	1,27	1,25	1,23	1,22	≤ 1,25 (Anonim, 2006)
	II	1,22	1,19	1,27	1,23	
	III	1,27	1,25	1,22	1,27	
	Rata-rata	1,25	1,23	1,24	1,24	
	SD	0,03	0,03	0,02	0,02	
Carr's Index (%)	I	21	20	19	18	16-20 = cukup (Anonim, 2006)
	II	18	16	21	19	
	III	21	20	18	21	
	Rata-rata	20,00	18,67	19,33	19,33	
	SD	1,73	2,31	1,53	1,53	

Mutu fisik yang diuji	Replikasi	Formula ODT Domperidone							
		F1		F2		F3		F4	
		ρ bulk	ρ tapped	ρ bulk	ρ tapped	ρ bulk	ρ tapped	ρ bulk	ρ tapped
Densitas serbuk	I	0,4741	0,6001	0,5066	0,6333	0,4932	0,6089	0,4941	0,6025
	II	0,7091	0,8648	0,6729	0,8011	0,7094	0,8980	0,6713	0,8288
	III	0,7081	0,8963	0,6692	0,8365	0,7026	0,8568	0,6752	0,8547
	Rata-rata	0,6304	0,7871	0,6162	0,7569	0,6351	0,7879	0,6135	0,7620
	SD	0,135	0,163	0,095	0,109	0,123	0,156	0,103	0,139

LAMPIRAN B

HASIL UJI KERAGAMAN BOBOT ODT DOMPERIDONE

FORMULA 1

No	Replikasi I		Replikasi II		Replikasi III	
	Bobot Tablet (mg)	Y (%)	Bobot Tablet (mg)	Y (%)	Bobot Tablet (mg)	Y (%)
1	104,4	100,01	110,5	105,57	110,7	109,83
2	102,7	98,38	109,3	104,42	110,0	109,14
3	106,5	102,02	110,4	105,47	109,3	108,44
4	99,8	95,60	105,2	100,51	106,2	105,37
5	97,5	93,40	101,3	96,78	108,6	107,75
6	103,6	99,24	107,4	102,61	109,3	108,44
7	104,2	99,82	108,8	103,95	109,8	108,94
8	100,4	96,18	110,1	105,19	107,1	106,26
9	97,8	93,69	106,5	101,75	105,6	104,77
10	98,2	94,07	104,4	99,74	110,1	109,24
Rata-rata	101,51	97,24	107,39	102,60	108,67	107,82
PK (%)	97,24		102,60		107,82	
SD	3,05		2,91		1,75	
KV	3,14		2,83		1,62	

FORMULA 2

No	Replikasi I		Replikasi II		Replikasi III	
	Bobot Tablet (mg)	**Y (%)**	**Bobot Tablet (mg)**	**Y (%)**	**Bobot Tablet (mg)**	**Y (%)**
1	106,5	101,66	105,2	101,59	108,4	106,38
2	101,4	96,79	109,2	105,45	105,8	103,83
3	100,6	96,02	108,4	104,68	106,3	104,32
4	110,3	105,28	108,3	104,59	108,3	106,28
5	104,5	99,75	104,8	101,21	107,6	105,59
6	100,4	95,83	106,2	102,56	107,2	105,20
7	101,8	97,17	108,7	104,97	106,7	104,71
8	103,7	98,98	109,5	105,74	108,2	106,18
9	108,1	103,18	108,0	104,30	106,6	104,61
10	112,4	107,29	107,6	103,91	108,1	106,08
Rata-rata	104,97	100,20	107,59	103,90	107,32	105,32
PK (%)	100,20		103,90		105,32	
SD	4,03		1,58		0,92	
KV	4,02		1,53		0,87	

FORMULA 3

No	Replikasi I		Replikasi II		Replikasi III	
	Bobot Tablet (mg)	**Y (%)**	**Bobot Tablet (mg)**	**Y (%)**	**Bobot Tablet (mg)**	**Y (%)**
1	103,8	106,55	102,6	97,04	110,4	107,20
2	101,8	104,50	100,5	95,05	110,3	107,11
3	98,4	101,01	102,4	96,85	106,8	103,71
4	100,8	103,47	104,6	98,93	110,6	107,40
5	101,4	104,09	102,7	97,13	107,3	104,19
6	103,5	106,25	100,1	94,67	110,9	107,69
7	100,6	103,27	100,5	95,05	110,5	107,30
8	99,5	102,14	101,2	95,71	110,6	107,40
9	100,7	103,37	100,7	95,24	106,3	103,22
10	100,3	102,96	101,4	95,90	105,4	102,35
Rata-rata	101,08	103,76	101,67	96,16	108,91	105,76
PK (%)	103,76		96,16		105,76	
SD	1,70		1,32		2,11	
KV	1,64		1,37		2,00	

FORMULA 4

No	Replikasi I		Replikasi II		Replikasi III	
	Bobot Tablet (mg)	Y (%)	Bobot Tablet (mg)	Y (%)	Bobot Tablet (mg)	Y (%)
1	105,3	106,87	106,8	100,85	103,1	101,79
2	104,4	105,95	108,3	102,27	105,0	103,66
3	107,1	108,69	108,0	101,98	103,5	102,18
4	106,2	107,78	107,2	101,23	102,6	101,29
5	104,8	106,36	105,8	99,91	103,8	102,48
6	105,6	107,17	106,1	100,19	104,2	102,87
7	99,9	101,39	106,6	100,66	105,5	104,16
8	100,4	101,89	104,0	98,21	103,1	101,79
9	104,4	105,95	105,8	99,91	105,7	104,35
10	106,0	107,58	107,5	101,51	104,3	102,97
Rata-rata	104,41	105,96	106,61	100,67	104,08	102,75
PK (%)	105,96		100,67		102,75	
SD	2,43		1,19		1,04	
KV	2,30		1,18		1,02	

LAMPIRAN C

HASIL UJI KESERAGAMAN KANDUNGAN ODT DOMPERIDONE

Hasil Uji Keseragaman Kandungan Tablet Formula 1 Replikasi I

Abs	W tablet (mg)	W sampel (mg)	C sampel (µg/ml)	C teoritis (µg/ml)	Kadar (%)
0,239	104,4	96,0	7,36	7,36	100,10
0,241	102,7	95,6	7,43	7,45	99,83
0,238	106,5	100,3	7,33	7,53	97,27
0,242	99,8	95,1	7,47	7,62	97,99
0,245	97,5	92,8	7,58	7,61	99,50
0,248	103,6	99,6	7,68	7,69	99,88
0,243	104,2	99,7	7,51	7,65	98,05
0,242	100,4	97,2	7,47	7,75	96,45
0,252	97,8	94,5	7,82	7,73	101,21
0,246	98,2	94,9	7,61	7,73	98,45
				Rata-rata	98,87
				SD	1,47
				KV	1,48

Hasil Uji Keseragaman Kandungan Tablet Formula 1 Replikasi II

Abs	W tablet (mg)	W sampel (mg)	C sampel (µg/ml)	C teoritis (µg/ml)	Kadar (%)
0,244	110,5	104,3	7,54	7,55	99,86
0,258	109,3	104,1	8,04	7,62	105,46
0,253	110,4	105,8	7,86	7,67	102,50
0,248	105,2	99,6	7,68	7,57	101,42
0,239	101,3	95,8	7,36	7,57	97,33
0,241	107,4	102,2	7,43	7,61	97,66
0,255	108,8	104,7	7,93	7,70	103,00
0,251	110,1	105,5	7,79	7,67	101,59
0,258	106,5	101,8	8,04	7,65	105,08
0,249	104,4	101,4	7,72	7,77	99,32
				Rata-rata	101,32
				SD	2,81
				KV	2,77

Hasil Uji Keseragaman Kandungan Tablet Formula 1 Replikasi III

Abs	W tablet (mg)	W sampel (mg)	C sampel (µg/ml)	C teoritis (µg/ml)	Kadar (%)
0,253	110,7	104,7	7,86	7,57	103,86
0,248	110,0	105,2	7,68	7,65	100,41
0,246	109,3	103	7,61	7,54	100,96
0,250	106,2	100,7	7,75	7,59	102,20
0,244	108,6	104,2	7,54	7,68	98,24
0,245	109,3	105,9	7,58	7,75	97,74
0,255	109,8	103,8	7,93	7,56	104,85
0,253	107,1	102,4	7,86	7,65	102,74
0,249	105,6	100,3	7,72	7,60	101,56
0,257	110,1	106	8,00	7,70	103,87
				Rata-rata	101,64
				SD	2,37
				KV	2,33

Hasil Uji Keseragaman Kandungan Tablet Formula 2 Replikasi I

Abs	W tablet (mg)	W sampel (mg)	C sampel (µg/ml)	C teoritis (µg/ml)	Kadar (%)
0,245	106,5	100,1	7,58	7,52	100,75
0,248	101,4	98,2	7,68	7,75	99,15
0,250	100,6	94,3	7,75	7,50	103,38
0,251	110,3	104,9	7,79	7,61	102,36
0,248	104,5	100,0	7,68	7,66	100,35
0,245	100,4	95,8	7,58	7,63	99,25
0,253	101,8	96,2	7,86	7,56	103,95
0,255	103,7	98,7	7,93	7,61	104,14
0,246	108,1	102,4	7,61	7,58	100,44
0,247	112,4	108,3	7,65	7,71	99,20
				Rata-rata	101,30
				SD	1,99
				KV	1,97

Hasil Uji Keseragaman Kandungan Tablet Formula 2 Replikasi II

Abs	W tablet (mg)	W sampel (mg)	C sampel (µg/ml)	C teoritis (µg/ml)	Kadar (%)
0,245	105,2	99,9	7,58	7,60	99,72
0,246	109,2	103,7	7,61	7,60	100,19
0,248	108,4	104,5	7,68	7,71	99,61
0,246	108,3	103,8	7,61	7,67	99,27
0,252	104,8	100,1	7,82	7,64	102,38
0,254	106,2	100,2	7,89	7,55	104,58
0,255	108,7	103,8	7,93	7,64	103,80
0,251	109,5	105,0	7,79	7,67	101,52
0,248	108,0	103,4	7,68	7,66	100,30
0,244	107,6	101,7	7,54	7,56	99,73
				Rata-rata	101,11
				SD	1,89
				KV	1,87

Hasil Uji Keseragaman Kandungan Tablet Formula 2 Replikasi III

Abs	W tablet (mg)	W sampel (mg)	C sampel (µg/ml)	C teoritis (µg/ml)	Kadar (%)
0,247	108,4	103,8	7,65	7,66	99,82
0,256	105,8	100,1	7,96	7,57	105,23
0,254	106,3	100,7	7,89	7,58	104,16
0,248	108,3	102,4	7,68	7,56	101,56
0,249	107,6	102,8	7,72	7,64	100,97
0,252	107,2	102,3	7,82	7,63	102,48
0,250	106,7	100,3	7,75	7,52	103,09
0,257	108,2	104,5	8,00	7,73	103,54
0,251	106,6	103,8	7,79	7,79	99,98
0,254	108,1	104,2	7,89	7,71	102,37
				Rata-rata	102,32
				SD	1,77
				KV	1,73

Hasil Uji Keseragaman Kandungan Tablet Formula 3 Replikasi I

Abs	W tablet (mg)	W sampel (mg)	C sampel (µg/ml)	C teoritis (µg/ml)	Kadar (%)
0,256	103,8	100,6	7,96	7,75	102,73
0,251	101,8	96,3	7,79	7,57	102,91
0,248	98,4	94,2	7,68	7,66	100,31
0,245	100,8	96,2	7,58	7,63	99,23
0,249	101,4	97,3	7,72	7,68	100,53
0,253	103,5	96,5	7,86	7,46	105,36
0,255	100,6	94,7	7,93	7,53	105,29
0,251	99,5	93,6	7,79	7,53	103,49
0,245	100,7	95,1	7,58	7,56	100,28
0,247	100,3	94,8	7,65	7,56	101,13
				Rata-rata	102,12
				SD	2,16
				KV	2,11

Hasil Uji Keseragaman Kandungan Tablet Formula 3 Replikasi II

Abs	W tablet (mg)	W sampel (mg)	C sampel (µg/ml)	C teoritis (µg/ml)	Kadar (%)
0,249	102,6	98,2	7,72	7,66	100,79
0,243	100,5	94,5	7,51	7,52	99,77
0,242	102,4	94,9	7,47	7,41	100,75
0,238	104,6	95,6	7,33	7,31	100,23
0,239	102,7	95,2	7,36	7,42	99,30
0,240	100,1	95,7	7,40	7,65	96,74
0,244	100,5	96,1	7,54	7,65	98,57
0,246	101,2	97,0	7,61	7,67	99,26
0,240	100,7	95,7	7,40	7,60	97,32
0,242	101,4	96,4	7,47	7,61	98,22
				Rata-rata	99,10
				SD	1,38
				KV	1,39

Hasil Uji Keseragaman Kandungan Tablet Formula 3 Replikasi III

Abs	W tablet (mg)	W sampel (mg)	C sampel (µg/ml)	C teoritis (µg/ml)	Kadar (%)
0,260	110,4	106,3	8,11	7,70	105,23
0,254	110,3	105,8	7,89	7,67	102,87
0,255	106,8	100,7	7,93	7,54	105,12
0,249	110,6	103,9	7,72	7,52	102,69
0,247	107,3	102,6	7,65	7,65	99,96
0,252	110,9	106,3	7,82	7,67	102,02
0,256	110,5	104,7	7,96	7,58	105,07
0,258	110,6	106,1	8,04	7,67	104,70
0,249	106,3	100,5	7,72	7,56	102,03
0,257	105,4	100,7	8,00	7,64	104,67
				Rata-rata	103,44
				SD	1,79
				KV	1,73

Hasil Uji Keseragaman Kandungan Tablet Formula 4 Replikasi I

Abs	W tablet (mg)	W sampel (mg)	C sampel (µg/ml)	C teoritis (µg/ml)	Kadar (%)
0,258	105,3	100,7	8,04	7,65	105,03
0,245	104,4	100,1	7,58	7,67	98,77
0,247	107,1	102,4	7,65	7,65	99,97
0,251	106,2	101,8	7,79	7,67	101,56
0,256	104,8	98,6	7,96	7,53	105,82
0,249	105,6	102,1	7,72	7,73	99,77
0,252	99,9	93,5	7,82	7,49	104,49
0,251	100,4	94,9	7,79	7,56	102,99
0,255	104,4	98,7	7,93	7,56	104,84
0,249	106,0	101,4	7,72	7,65	100,84
				Rata-rata	102,41
				SD	2,55
				KV	2,49

Hasil Uji Keseragaman Kandungan Tablet Formula 4 Replikasi II

Abs	W tablet (mg)	W sampel (mg)	C sampel (µg/ml)	C teoritis (µg/ml)	Kadar (%)
0,250	106,8	102,3	7,75	7,66	101,17
0,249	108,3	103,6	7,72	7,65	100,84
0,253	108,0	104,7	7,86	7,76	101,33
0,251	107,2	102,5	7,79	7,65	101,81
0,250	105,8	100,3	7,75	7,58	102,22
0,246	106,1	101,8	7,61	7,68	99,16
0,250	106,6	102,4	7,75	7,68	100,88
0,247	104,0	100,1	7,65	7,70	99,31
0,249	105,8	100,5	7,72	7,60	101,55
0,253	107,5	104,0	7,86	7,74	101,54
				Rata-rata	100,98
				SD	1,01
				KV	1,00

Hasil Uji Keseragaman Kandungan Tablet Formula 4 Replikasi III

Abs	W tablet (mg)	W sampel (mg)	C sampel (µg/ml)	C teoritis (µg/ml)	Kadar (%)
0,244	103,1	95,1	7,54	7,38	102,19
0,240	105,0	97,4	7,40	7,42	99,71
0,243	103,5	96,9	7,51	7,49	100,21
0,245	102,6	95,2	7,58	7,42	102,06
0,242	103,8	95,2	7,47	7,34	101,81
0,241	104,2	96,8	7,43	7,43	100,04
0,248	105,5	100,3	7,68	7,61	101,00
0,250	103,1	100,0	7,75	7,76	99,91
0,252	105,7	101,2	7,82	7,66	102,14
0,254	104,3	101,4	7,89	7,78	101,50
				Rata-rata	101,06
				SD	1,01
				KV	1,00

LAMPIRAN D

HASIL UJI KESERAGAMAN UKURAN ODT DOMPERIDONE

FORMULA 1

No	Replikasi I		Replikasi II		Replikasi III	
	Diameter Tablet (cm)	Tebal Tablet (cm)	Diameter Tablet (cm)	Tebal Tablet (cm)	Diameter Tablet (cm)	Tebal Tablet (cm)
1	0,610	0,340	0,615	0,325	0,605	0,350
2	0,610	0,350	0,610	0,335	0,610	0,340
3	0,605	0,340	0,610	0,350	0,605	0,345
4	0,610	0,345	0,605	0,350	0,610	0,340
5	0,610	0,340	0,610	0,340	0,610	0,340
6	0,615	0,330	0,610	0,320	0,610	0,340
7	0,605	0,340	0,610	0,330	0,610	0,340
8	0,610	0,345	0,615	0,320	0,610	0,330
9	0,610	0,340	0,610	0,320	0,615	0,325
10	0,610	0,350	0,605	0,350	0,610	0,330
11	0,615	0,330	0,605	0,345	0,610	0,340
12	0,610	0,345	0,610	0,330	0,610	0,345
13	0,605	0,350	0,610	0,340	0,605	0,350
14	0,610	0,350	0,610	0,330	0,610	0,330
15	0,610	0,350	0,610	0,325	0,610	0,330
16	0,610	0,335	0,610	0,340	0,605	0,355
17	0,605	0,350	0,605	0,350	0,610	0,340
18	0,605	0,350	0,610	0,350	0,610	0,330
19	0,610	0,350	0,615	0,325	0,605	0,350
20	0,610	0,350	0,615	0,320	0,610	0,340
Rata-rata	0,609	0,344	0,610	0,335	0,609	0,340
SD		0,007		0,012		0,008
KV		1,978		3,477		2,432

FORMULA 2

No	Replikasi I		Replikasi II		Replikasi III	
	Diameter Tablet (cm)	Tebal Tablet (cm)	Diameter Tablet (cm)	Tebal Tablet (cm)	Diameter Tablet (cm)	Tebal Tablet (cm)
1	0,615	0,345	0,610	0,350	0,610	0,340
2	0,610	0,350	0,610	0,350	0,610	0,340
3	0,615	0,345	0,605	0,365	0,610	0,340
4	0,610	0,350	0,610	0,360	0,605	0,350
5	0,610	0,360	0,610	0,340	0,610	0,335
6	0,610	0,360	0,610	0,360	0,610	0,340
7	0,615	0,340	0,610	0,355	0,610	0,345
8	0,610	0,365	0,610	0,340	0,610	0,340
9	0,605	0,370	0,605	0,350	0,610	0,340
10	0,610	0,360	0,610	0,345	0,610	0,330
11	0,610	0,370	0,610	0,340	0,615	0,325
12	0,605	0,370	0,615	0,335	0,610	0,330
13	0,610	0,370	0,605	0,360	0,605	0,350
14	0,605	0,385	0,610	0,350	0,610	0,340
15	0,610	0,370	0,610	0,350	0,610	0,325
16	0,605	0,380	0,610	0,350	0,605	0,350
17	0,610	0,360	0,615	0,335	0,615	0,315
18	0,610	0,365	0,610	0,350	0,610	0,340
19	0,605	0,370	0,605	0,360	0,610	0,340
20	0,610	0,360	0,610	0,350	0,610	0,340
Rata-rata	0,610	0,362	0,610	0,350	0,610	0,338
SD		0,012		0,009		0,009
KV		3,244		2,475		2,651

FORMULA 3

No	Replikasi I		Replikasi II		Replikasi III	
	Diameter Tablet (cm)	Tebal Tablet (cm)	Diameter Tablet (cm)	Tebal Tablet (cm)	Diameter Tablet (cm)	Tebal Tablet (cm)
1	0,610	0,340	0,605	0,350	0,610	0,330
2	0,610	0,330	0,610	0,340	0,605	0,325
3	0,610	0,335	0,605	0,350	0,605	0,330
4	0,610	0,330	0,610	0,340	0,610	0,320
5	0,610	0,330	0,610	0,340	0,610	0,320
6	0,610	0,345	0,610	0,350	0,610	0,320
7	0,610	0,330	0,610	0,340	0,615	0,315
8	0,610	0,335	0,610	0,345	0,610	0,330
9	0,610	0,330	0,610	0,340	0,615	0,315
10	0,610	0,330	0,605	0,350	0,610	0,330
11	0,610	0,330	0,610	0,345	0,605	0,320
12	0,610	0,330	0,610	0,340	0,615	0,315
13	0,610	0,335	0,610	0,340	0,610	0,330
14	0,605	0,350	0,610	0,340	0,610	0,325
15	0,610	0,330	0,610	0,335	0,610	0,320
16	0,610	0,335	0,610	0,335	0,605	0,340
17	0,610	0,330	0,610	0,335	0,615	0,310
18	0,610	0,330	0,610	0,340	0,615	0,315
19	0,610	0,340	0,615	0,335	0,610	0,315
20	0,605	0,350	0,610	0,340	0,610	0,320
Rata-rata	0,610	0,335	0,610	0,342	0,610	0,322
SD		0,007		0,005		0,008
KV		2,026		1,510		2,333

FORMULA 4

No	Replikasi I		Replikasi II		Replikasi III	
	Diameter Tablet (cm)	Tebal Tablet (cm)	Diameter Tablet (cm)	Tebal Tablet (cm)	Diameter Tablet (cm)	Tebal Tablet (cm)
1	0,610	0,375	0,610	0,360	0,615	0,330
2	0,610	0,380	0,605	0,370	0,610	0,340
3	0,615	0,375	0,610	0,360	0,610	0,340
4	0,610	0,380	0,610	0,360	0,610	0,335
5	0,610	0,380	0,610	0,360	0,610	0,300
6	0,610	0,380	0,610	0,360	0,610	0,340
7	0,610	0,385	0,610	0,365	0,610	0,340
8	0,605	0,390	0,610	0,360	0,615	0,330
9	0,610	0,380	0,610	0,360	0,615	0,330
10	0,610	0,380	0,610	0,360	0,610	0,335
11	0,610	0,380	0,610	0,360	0,610	0,345
12	0,605	0,390	0,610	0,360	0,610	0,340
13	0,605	0,390	0,610	0,360	0,610	0,340
14	0,610	0,375	0,610	0,365	0,610	0,340
15	0,610	0,380	0,610	0,360	0,605	0,350
16	0,615	0,375	0,615	0,355	0,605	0,345
17	0,610	0,380	0,610	0,360	0,610	0,340
18	0,610	0,380	0,610	0,360	0,610	0,340
19	0,610	0,380	0,610	0,365	0,610	0,345
20	0,610	0,380	0,610	0,360	0,610	0,340
Rata-rata	0,610	0,381	0,610	0,361	0,610	0,337
SD		0,005		0,003		0,010
KV		1,226		0,853		3,022

LAMPIRAN E

HASIL UJI KEKERASAN ODT DOMPERIDONE

Hasil Uji Kekerasan ODT Domperidone Replikasi I

No	Kekerasan ODT Domperidone (Kp)			
	Formula 1	**Formula 2**	**Formula 3**	**Formula 4**
1	2,9	2,2	2,8	2,1
2	2,7	2,8	3,3	3,3
3	3,1	2,3	3,4	3
4	3,4	2	3,8	2,3
5	2,4	2	3,5	2,2
6	3	3,8	2,9	1,9
7	2,1	2	3,6	2,3
8	3,1	2,2	3,2	2
9	2,2	2,7	3,1	2,5
10	2,9	2,2	3,3	2,2
Rata-rata	2,78	2,42	3,29	2,38
SD	0,42	0,56	0,31	0,44
KV	15,24	23,11	9,34	18,66

Hasil Uji Kekerasan ODT Domperidone Replikasi II

No	Kekerasan ODT Domperidone (Kp)			
	Formula 1	**Formula 2**	**Formula 3**	**Formula 4**
1	3,9	3,6	2,6	3,3
2	3,1	3,6	2,3	3,2
3	2,8	2,6	3,4	3,1
4	2,9	3	2,4	3
5	2,8	2,1	3,6	2,6
6	2,6	3,5	3,8	2,5
7	2,8	3,4	3,3	3,1
8	3,3	3,1	3,8	2,9
9	3,5	2,4	3,9	2,7
10	3,1	2,2	2,7	2,3
Rata-rata	3,08	2,95	3,18	2,87
SD	0,39	0,59	0,62	0,33
KV	12,79	19,85	19,54	11,50

Hasil Uji Kekerasan ODT Domperidone Replikasi III

No	Kekerasan ODT Domperidone (Kp)			
	Formula 1	**Formula 2**	**Formula 3**	**Formula 4**
1	2,2	3,3	2,9	3,3
2	2,8	3,9	2,5	2,5
3	3,1	2,5	2,3	3,2
4	2,7	3,7	3,6	2,7
5	3,9	3,3	3,7	3,7
6	3,6	3,4	3,3	3,2
7	3,9	3,1	3,5	2,8
8	2,8	3	3,2	3,3
9	3,4	3,8	3,5	3,6
10	3,4	2,6	3,3	2,3
Rata-rata	3,18	3,26	3,18	3,06
SD	0,56	0,47	0,47	0,46
KV	17,53	14,55	14,81	15,19

LAMPIRAN F

HASIL UJI KERAPUHAN ODT DOMPERIDONE

Formula	Rep	Berat awal (gram)	Berat akhir (gram)	Kerapuhan (%)	Rata-rata	SD	KV
1	I	1,98	1,95	1,52	0,83	0,60	71,89
	II	2,07	2,06	0,48			
	III	2,06	2,05	0,49			
2	I	2,01	1,98	1,49	0,82	0,59	71,69
	II	2,13	2,12	0,47			
	III	2,05	2,04	0,49			
3	I	1,94	1,93	0,52	0,34	0,29	86,68
	II	2,04	2,03	0,49			
	III	2,03	2,03	0,00			
4	I	2,01	1,98	1,49	0,81	0,59	72,94
	II	2,23	2,22	0,45			
	III	2,04	2,03	0,49			

LAMPIRAN G

HASIL UJI WAKTU HANCUR ODT DOMPERIDONE

Hasil Uji Waktu Hancur ODT Domperidone Replikasi I

No	Waktu Hancur (detik)			
	Formula 1	**Formula 2**	**Formula 3**	**Formula 4**
1	40	28	159	40
2	38	26	121	38
3	38	32	151	45
4	49	31	148	38
5	36	32	164	39
Rata-rata	40,2	29,8	148,6	40
SD	5,12	2,68	16,68	2,92
KV	12,73	9,00	11,23	7,29

Hasil Uji Waktu Hancur ODT Domperidone Replikasi II

No	Waktu Hancur (detik)			
	Formula 1	**Formula 2**	**Formula 3**	**Formula 4**
1	65	37	93	59
2	82	37	87	72
3	81	34	99	68
4	75	39	103	61
5	77	30	97	65
Rata-rata	76	35,4	95,8	65
SD	6,78	3,51	6,10	5,24
KV	8,92	9,91	6,37	8,07

Hasil Uji Waktu Hancur ODT Domperidone Replikasi III

No	Waktu Hancur (detik)			
	Formula 1	**Formula 2**	**Formula 3**	**Formula 4**
1	36	32	110	67
2	53	38	167	65
3	30	28	172	83
4	44	35	113	66
5	43	32	117	70
Rata-rata	41,2	33	135,8	70,2
SD	8,70	3,74	30,91	7,40
KV	21,12	11,34	22,76	10,54

LAMPIRAN H

HASIL UJI WAKTU PEMBASAHAN DAN RASIO ABSORBSI AIR ODT DOMPERIDONE

Hasil Uji Waktu Pembasahan dan Rasio Absorpsi Air Replikasi I

FORMULA 1

No	Waktu Pembasahan dan Rasio Absorpsi Air			
	Wb	**Wa**	**Waktu (detik)**	**Rasio (%)**
1	106,0	133,3	41	25,75
2	104,5	128,3	25	22,78
3	96,4	128,1	37	32,88
4	98,6	120,2	45	21,91
5	97,2	125,0	43	28,60
6	99,0	130,2	35	31,52
Rata-rata	100,28	127,52	37,67	27,24
SD	3,99	4,50	7,23	4,53
KV	3,98	3,53	19,19	16,63

Keterangan : Wb = berat sebelum terbasahi
Wa = berat setelah terbasahi

FORMULA 2

No	Waktu Pembasahan dan Rasio Absorpsi Air			
	Wb	**Wa**	**Waktu (detik)**	**Rasio (%)**
1	103,0	173,0	117	67,96
2	100,5	144,9	83	44,18
3	101,5	155,1	74	52,81
4	113,3	164,0	89	44,75
5	100,2	146,3	95	46,01
6	104,5	163,0	90	55,98
Rata-rata	103,83	157,72	91,33	51,95
SD	4,91	10,98	14,49	9,17
KV	4,73	6,96	15,86	17,66

Keterangan : Wb = berat sebelum terbasahi
Wa = berat setelah terbasahi

FORMULA 3

No	Waktu Pembasahan dan Rasio Absorpsi Air			
	Wb	**Wa**	**Waktu (detik)**	**Rasio (%)**
1	101,8	133,5	104	31,14
2	98,3	130,7	63	32,96
3	100,9	123,8	47	22,70
4	101,2	119,2	47	17,79
5	103,1	129,2	93	25,32
6	100,2	114,1	46	13,87
Rata-rata	100,92	125,08	66,67	23,96
SD	1,61	7,43	25,70	7,43
KV	1,60	5,94	38,54	31,00

Keterangan : Wb = berat sebelum terbasahi
Wa = berat setelah terbasahi

FORMULA 4

No	Waktu Pembasahan dan Rasio Absorpsi Air			
	Wb	**Wa**	**Waktu (detik)**	**Rasio (%)**
1	105,6	150,0	168	42,05
2	106,0	152,8	172	44,15
3	104,4	146,0	131	39,85
4	107,1	160,0	200	49,39
5	99,9	145,4	156	45,55
6	104,9	151,0	175	43,95
Rata-rata	104,65	150,87	167,00	44,15
SD	2,51	5,32	22,79	3,24
KV	2,40	3,53	13,64	7,33

Keterangan : Wb = berat sebelum terbasahi
Wa = berat setelah terbasahi

Hasil Uji Waktu Pembasahan dan Rasio Absorpsi Air Replikasi II

FORMULA 1

No	Waktu Pembasahan dan Rasio Absorpsi Air			
	Wb	**Wa**	**Waktu (detik)**	**Rasio (%)**
1	109,0	134,2	38	23,12
2	110,2	143,6	42	30,31
3	110,9	138,9	39	25,25
4	107,7	145,5	32	35,10
5	108,2	152,8	35	41,22
6	109,8	151,9	37	38,34
Rata-rata	109,30	144,48	37,17	32,22
SD	1,22	7,25	3,43	7,24
KV	1,12	5,02	9,23	22,46

Keterangan : Wb = berat sebelum terbasahi
Wa = berat setelah terbasahi

FORMULA 2

No	Waktu Pembasahan dan Rasio Absorpsi Air			
	Wb	**Wa**	**Waktu (detik)**	**Rasio (%)**
1	108,6	174,1	82	60,31
2	105,2	170,0	84	61,60
3	109,6	170,4	60	55,47
4	109,2	178,3	80	63,28
5	109,0	170,9	75	56,79
6	108,3	169,3	73	56,33
Rata-rata	108,32	172,17	75,67	58,96
SD	1,59	3,43	8,73	3,20
KV	1,47	2,00	11,54	5,43

Keterangan : Wb = berat sebelum terbasahi
Wa = berat setelah terbasahi

FORMULA 3

No	Waktu Pembasahan dan Rasio Absorpsi Air			
	Wb	**Wa**	**Waktu (detik)**	**Rasio (%)**
1	104,2	139,6	54	33,97
2	104,6	143,7	63	37,38
3	102,6	139,6	55	36,06
4	102,7	151,7	66	47,71
5	100,5	136,5	49	35,82
6	101,3	137,6	54	35,83
Rata-rata	102,65	141,45	56,83	37,80
SD	1,59	5,59	6,37	4,98
KV	1,55	3,95	11,21	13,17

Keterangan : Wb = berat sebelum terbasahi
Wa = berat setelah terbasahi

FORMULA 4

No	Waktu Pembasahan dan Rasio Absorpsi Air			
	Wb	**Wa**	**Waktu (detik)**	**Rasio (%)**
1	108,3	164,5	147	51,89
2	106,7	166,1	111	55,67
3	107,9	178,8	80	65,71
4	108,0	180,0	79	66,67
5	105,4	163,4	89	55,03
6	107,6	167,8	125	55,95
Rata-rata	107,32	170,10	105,17	58,49
SD	1,09	7,37	27,41	6,15
KV	1,01	4,33	26,06	10,51

Keterangan : Wb = berat sebelum terbasahi
Wa = berat setelah terbasahi

Hasil Uji Waktu Pembasahan dan Rasio Absorpsi Air Replikasi III

FORMULA 1

No	Waktu Pembasahan dan Rasio Absorpsi Air			
	Wb	**Wa**	**Waktu (detik)**	**Rasio (%)**
1	110,2	149,0	31	35,21
2	110,1	151,3	29	37,42
3	109,3	162,2	27	48,40
4	109,3	160,2	33	46,57
5	108,5	142,5	37	31,34
6	109,6	141,6	26	29,20
Rata-rata	109,50	151,13	30,50	38,02
SD	0,62	8,66	4,09	7,89
KV	0,57	5,73	13,40	20,76

Keterangan : Wb = berat sebelum terbasahi
Wa = berat setelah terbasahi

FORMULA 2

No	Waktu Pembasahan dan Rasio Absorpsi Air			
	Wb	**Wa**	**Waktu (detik)**	**Rasio (%)**
1	105,9	167,8	64	58,45
2	105,5	153,3	40	45,31
3	107,8	172,3	57	59,83
4	108,6	170,1	50	56,63
5	106,0	176,2	60	66,23
6	105,6	178,0	45	68,56
Rata-rata	106,57	169,62	52,67	59,17
SD	1,30	8,84	9,24	8,22
KV	1,22	5,21	17,55	13,89

Keterangan : Wb = berat sebelum terbasahi
Wa = berat setelah terbasahi

FORMULA 3

No	Waktu Pembasahan dan Rasio Absorpsi Air			
	Wb	**Wa**	**Waktu (detik)**	**Rasio (%)**
1	110,0	140,0	90	27,27
2	111,8	142,0	97	27,01
3	106,6	126,0	51	18,20
4	111,5	148,3	68	33,00
5	111,8	137,3	73	22,81
6	113,0	136,1	52	20,44
Rata-rata	110,78	138,28	71,83	24,79
SD	2,26	7,40	19,01	5,38
KV	2,04	5,35	26,46	21,71

Keterangan : Wb = berat sebelum terbasahi
Wa = berat setelah terbasahi

FORMULA 4

No	Waktu Pembasahan dan Rasio Absorpsi Air			
	Wb	**Wa**	**Waktu (detik)**	**Rasio (%)**
1	105,0	152,8	74	45,52
2	104,3	162,4	77	55,70
3	105,5	165,7	79	57,06
4	102,2	143,1	97	40,02
5	103,8	145,3	63	39,98
6	104,8	166,7	65	59,06
Rata-rata	104,27	156,00	75,83	49,56
SD	1,17	10,40	12,21	8,76
KV	1,12	6,67	16,09	17,67

Keterangan : Wb = berat sebelum terbasahi
Wa = berat setelah terbasahi

LAMPIRAN I

HASIL UJI STABILITAS WAKTU HANCUR ODT DOMPERIDONE

No	Waktu Hancur (detik) Replikasi I			
	Formula 1	**Formula 2**	**Formula 3**	**Formula 4**
1	29	28	94	51
2	38	38	105	51
3	43	30	108	58
4	34	26	95	55
5	27	28	87	56
Rata-rata	34,2	30	97,8	54,2
SD	6,53	4,69	8,58	3,11
KV	19,11	15,63	8,78	5,75

No	Waktu Hancur (detik) Replikasi II			
	Formula 1	**Formula 2**	**Formula 3**	**Formula 4**
1	37	30	90	56
2	37	33	87	55
3	38	31	90	53
4	35	25	100	48
5	36	28	100	55
Rata-rata	36,6	29,4	93,4	53,4
SD	1,14	3,05	6,15	3,21
KV	3,12	10,37	6,58	6,01

No	Waktu Hancur (detik) Replikasi III			
	Formula 1	**Formula 2**	**Formula 3**	**Formula 4**
1	29	26	95	42
2	30	26	93	52
3	41	28	100	49
4	34	26	103	60
5	35	26	102	50
Rata-rata	33,8	26,4	98,6	50,6
SD	4,76	0,89	4,39	6,47
KV	14,10	3,39	4,46	12,78

LAMPIRAN J

HASIL UJI STABILITAS WAKTU PEMBASAHAN ODT DOMPERIDONE

No	Waktu Pembasahan (detik) Replikasi I			
	Formula 1	**Formula 2**	**Formula 3**	**Formula 4**
1	51	58	54	121
2	57	56	56	107
3	55	57	40	116
4	53	51	42	97
5	56	57	47	112
6	54	50	48	108
Rata-rata	54,33	54,83	47,83	110,17
SD	2,16	3,43	6,34	8,28
KV	3,98	6,26	13,25	7,52

No	Waktu Pembasahan (detik) Replikasi II			
	Formula 1	**Formula 2**	**Formula 3**	**Formula 4**
1	43	57	47	131
2	40	59	46	135
3	38	58	48	127
4	30	59	45	141
5	31	63	50	134
6	30	65	51	127
Rata-rata	35,33	60,17	47,83	132,50
SD	5,72	3,13	2,32	5,36
KV	16,18	5,19	4,84	4,04

No	Waktu Pembasahan (detik) Replikasi III			
	Formula 1	**Formula 2**	**Formula 3**	**Formula 4**
1	53	60	55	108
2	40	63	60	94
3	45	63	52	132
4	52	62	58	112
5	48	57	46	110
6	58	70	57	109
Rata-rata	49,33	62,50	54,67	110,83
SD	6,38	4,32	5,05	12,21
KV	12,93	6,92	9,23	11,01

LAMPIRAN K

HASIL UJI PENETAPAN KADAR ODT DOMPERIDONE

Hasil Uji Penetapan Kadar ODT Dompeidone
Formula 1

Rep	Massa /tablet	Massa (mg)	Abs.	C sampel (ppm)	C teoritis (ppm)	% Kadar	Rata-rata	SD	KV (%)
1	99,585	100,6	0,253	7,86	8,08	97,24			
2	109,47	100,1	0,243	7,51	7,32	102,60	102,55	5,29	5,16
3	105,14	100,1	0,263	8,21	7,62	107,82			

Hasil Uji Penetapan Kadar ODT Dompeidone
Formula 2

Rep	Massa /tablet	Massa (mg)	Abs.	C sampel (ppm)	C teoritis (ppm)	% Kadar	Rata-rata	SD	KV (%)
1	103,97	100,1	0,249	7,72	7,70	100,20			
2	108,85	100,6	0,248	7,68	7,39	103,90	103,14	2,64	2,56
3	106,42	100,6	0,256	7,96	7,56	105,32			

Hasil Uji Penetapan Kadar ODT Dompeidone
Formula 3

Rep	Massa /tablet	Massa (mg)	Abs.	C sampel (ppm)	C teoritis (ppm)	% Kadar	Rata-rata	SD	KV (%)
1	99,35	100,4	0,268	8,39	8,08	103,76			
2	103,185	100,2	0,242	7,47	7,77	96,16	101,89	5,07	4,97
3	110,245	100,1	0,248	7,68	7,26	105,76			

Hasil Uji Penetapan Kadar ODT Dompeidone
Formula 4

Rep	Massa /tablet	Massa (mg)	Abs.	C sampel (ppm)	C teoritis (ppm)	% Kadar	Rata-rata	SD	KV (%)
1	105,815	100,3	0,258	8,04	7,58	105,96			
2	107,445	100,6	0,244	7,54	7,49	100,67	103,13	2,67	2,59
3	103,52	100,3	0,256	7,96	7,75	102,75			

LAMPIRAN L

HASIL UJI PENETAPAN KADAR TABLET PEMBANDING DOMPERIDONE

Hasil Uji Penetapan Kadar Tablet Pembanding 1

Rep	Massa /tablet (mg)	Massa (mg)	Abs.	C sampel (ppm)	C teoritis (ppm)	% Kadar	Rata-rata	SD	KV (%)
I	119,8	99,8	0,209	6,30	6,66	94,50			
II	123,4	100,3	0,211	6,37	6,50	97,95	96,50	1,78	1,85
III	121,1	101	0,214	6,47	6,67	97,04			

Hasil Uji Penetapan Kadar Tablet Pembanding 2

Rep	Massa /tablet (mg)	Massa (mg)	Abs.	C sampel (ppm)	C teoritis (ppm)	% Kadar	Rata-rata	SD	KV (%)
I	121,5	100,3	0,229	7,00	6,60	106,06			
II	125,4	99,7	0,213	6,44	6,36	101,24	103,05	2,62	2,55
III	124,6	100,1	0,216	6,55	6,43	101,84			

LAMPIRAN M

HASIL UJI DISOLUSI ODT DOMPERIDONE

FORMULA 1

Rep	t (menit)	Abs.	C (µg/ml)	Wt (mg)	% obat terlepas	AUC (µg menit / ml)
I	0	0	0	0	0	0
	0,5	0,232	7,12	6,4	65,87	1,60
	1	0,275	8,64	7,8	79,93	3,54
	2	0,29	9,17	8,2	84,83	8,01
	4	0,273	8,57	7,7	79,27	15,96
	6	0,263	8,21	7,4	76,00	15,10
	8	0,273	8,57	7,7	79,27	15,10
	10	0,259	8,07	7,3	74,70	14,97
	15	0,257	8,00	7,2	74,04	36,16
	20	0,249	7,72	6,9	71,43	35,36
	25	0,251	7,79	7,0	72,08	34,89
	30	0,247	7,65	6,9	70,77	34,73
					Σ AUC	215,42
					% ED	73,84

Rep	t (menit)	Abs.	C (µg/ml)	Wt (mg)	% obat terlepas	AUC (µg menit / ml)
II	0	0	0	0	0	0
	0,5	0,13	3,51	3,2	30,81	0,79
	1	0,206	6,20	5,6	54,37	2,18
	2	0,289	9,13	8,2	80,10	6,90
	4	0,291	9,20	8,3	80,72	16,50
	6	0,293	9,27	8,3	81,34	16,63
	8	0,295	9,34	8,4	81,96	16,75
	10	0,296	9,38	8,4	82,27	16,85
	15	0,292	9,24	8,3	81,03	41,88
	20	0,29	9,17	8,2	80,41	41,41
	25	0,29	9,17	8,2	80,41	41,25
	30	0,288	9,10	8,2	79,79	41,09
					Σ AUC	242,23
					% ED	78,70
III	0	0	0	0	0	0
	0,5	0,073	1,50	1,3	12,51	0,34
	1	0,281	8,85	8,0	73,86	2,33
	2	0,297	9,41	8,5	78,58	8,22
	4	0,303	9,63	8,7	80,35	17,13
	6	0,301	9,55	8,6	79,76	17,26
	8	0,302	9,59	8,6	80,05	17,23
	10	0,3	9,52	8,6	79,46	17,20
	15	0,311	9,91	8,9	82,71	43,71
	20	0,314	10,01	9,0	83,59	44,83
	25	0,298	9,45	8,5	78,87	43,79
	30	0,296	9,38	8,4	78,28	42,36
					Σ AUC	254,40
					% ED	78,65

FORMULA 2

Rep	t (menit)	Abs.	C (µg/ml)	Wt (mg)	% obat terlepas	AUC (µg menit / ml)
I	0	0	0	0	0	0
	0,5	0,219	6,66	6,0	59,80	1,50
	1	0,297	9,41	8,5	84,56	3,62
	2	0,287	9,06	8,2	81,38	8,31
	4	0,306	9,73	8,8	87,41	16,91
	6	0,303	9,63	8,7	86,46	17,42
	8	0,281	8,85	8,0	79,48	16,63
	10	0,284	8,95	8,1	80,43	16,02
	15	0,292	9,24	8,3	82,97	40,93
	20	0,274	8,60	7,7	77,25	40,13
	25	0,292	9,24	8,3	82,97	40,13
	30	0,303	9,63	8,7	86,46	42,44
					Σ AUC	244,05
					% ED	81,19
II	0	0	0	0	0	0
	0,5	0,174	5,07	4,6	43,89	1,14
	1	0,304	9,66	8,7	83,68	3,31
	2	0,328	10,51	9,5	91,03	9,08
	4	0,329	10,54	9,5	91,34	18,95
	6	0,323	10,33	9,3	89,50	18,79
	8	0,319	10,19	9,2	88,28	18,47
	10	0,318	10,16	9,1	87,97	18,31
	15	0,313	9,98	9,0	86,44	45,30
	20	0,307	9,77	8,8	84,60	44,43
	25	0,306	9,73	8,8	84,30	43,87
	30	0,316	10,08	9,1	87,36	44,59
					Σ AUC	266,24
					% ED	85,41

Rep	t (menit)	Abs.	C (µg/ml)	Wt (mg)	% obat terlepas	AUC (µg menit / ml)
III	0	0	0	0	0	0
	0,5	0,15	4,22	3,8	36,05	0,95
	1	0,283	8,92	8,0	76,22	2,96
	2	0,289	9,13	8,2	78,03	8,12
	4	0,291	9,20	8,3	78,63	16,50
	6	0,286	9,02	8,1	77,12	16,40
	8	0,296	9,38	8,4	80,14	16,56
	10	0,279	8,78	7,9	75,01	16,34
	15	0,281	8,85	8,0	75,61	39,66
	20	0,286	9,02	8,1	77,12	40,21
	25	0,296	9,38	8,4	80,14	41,41
	30	0,282	8,88	8,0	75,91	41,09
					Σ AUC	240,20
					% ED	76,02

FORMULA 3

Rep	t (menit)	Abs.	C (µg/ml)	Wt (mg)	% obat terlepas	AUC (µg menit / ml)
I	0	0	0	0	0	0
	0,5	0,092	2,17	2,0	18,82	0,49
	1	0,17	4,93	4,4	42,72	1,60
	2	0,296	9,38	8,4	81,34	6,44
	4	0,297	9,41	8,5	81,65	16,91
	6	0,285	8,99	8,1	77,97	16,56
	8	0,279	8,78	7,9	76,13	15,99
	10	0,283	8,92	8,0	77,36	15,93
	15	0,29	9,17	8,2	79,50	40,69
	20	0,272	8,53	7,7	73,99	39,82
	25	0,283	8,92	8,0	77,36	39,26
	30	0,285	8,99	8,1	77,97	40,29
					Σ AUC	233,97
					% ED	75,16
II	0	0	0	0	0	0
	0,5	0,087	1,99	1,8	18,65	0,45
	1	0,246	7,61	6,9	71,24	2,16
	2	0,3	9,52	8,6	89,10	7,71
	4	0,302	9,59	8,6	89,76	17,20
	6	0,299	9,48	8,5	88,77	17,17
	8	0,303	9,63	8,7	90,09	17,20
	10	0,297	9,41	8,5	88,11	17,13
	15	0,3	9,52	8,6	89,10	42,60
	20	0,297	9,41	8,5	88,11	42,60
	25	0,284	8,95	8,1	83,81	41,33
	30	0,294	9,31	8,4	87,12	41,09
					Σ AUC	246,63
					% ED	85,50

Rep	t (menit)	Abs.	C (µg/ml)	Wt (mg)	% obat terlepas	AUC (µg menit / ml)
III	0	0	0	0	0	0
	0,5	0,061	1,07	1,0	9,14	0,24
	1	0,218	6,62	6,0	56,35	1,73
	2	0,287	9,06	8,2	77,10	7,06
	4	0,31	9,87	8,9	84,02	17,04
	6	0,302	9,59	8,6	81,61	17,52
	8	0,309	9,84	8,9	83,72	17,48
	10	0,307	9,77	8,8	83,12	17,64
	15	0,309	9,84	8,9	83,72	44,11
	20	0,301	9,55	8,6	81,31	43,63
	25	0,301	9,55	8,6	81,31	43,00
	30	0,293	9,27	8,3	78,91	42,36
					Σ AUC	251,81
					% ED	79,37

FORMULA 4

Rep	t (menit)	Abs.	C (µg/ml)	Wt (mg)	% obat terlepas	AUC (µg menit / ml)
I	0	0	0	0	0	0
	0,5	0,115	2,98	2,7	25,33	0,67
	1	0,244	7,54	6,8	64,05	2,37
	2	0,294	9,31	8,4	79,05	7,58
	4	0,297	9,41	8,5	79,95	16,85
	6	0,313	9,98	9,0	84,75	17,45
	8	0,287	9,06	8,2	76,95	17,13
	10	0,298	9,45	8,5	80,25	16,66
	15	0,303	9,63	8,7	81,75	42,92
	20	0,29	9,17	8,2	77,85	42,28
	25	0,281	8,85	8,0	75,15	40,53
	30	0,287	9,06	8,2	76,95	40,29
					Σ AUC	244,74
					% ED	76,99
II	0	0	0	0	0	0
	0,5	0,099	2,42	2,2	21,61	0,54
	1	0,254	7,89	7,1	70,57	2,32
	2	0,31	9,87	8,9	88,26	8,00
	4	0,314	10,01	9,0	89,53	17,90
	6	0,307	9,77	8,8	87,31	17,80
	8	0,307	9,77	8,8	87,31	17,58
	10	0,306	9,73	8,8	87,00	17,55
	15	0,3	9,52	8,6	85,10	43,31
	20	0,293	9,27	8,3	82,89	42,28
	25	0,299	9,48	8,5	84,79	42,20
	30	0,294	9,31	8,4	83,21	42,28
					Σ AUC	251,77
					% ED	83,36

Rep	t (menit)	Abs.	C (µg/ml)	Wt (mg)	% obat terlepas	AUC (µg menit / ml)
III	0	0	0	0	0	0
	0,5	0,153	4,33	3,9	37,88	0,97
	1	0,262	8,18	7,4	71,62	2,81
	2	0,282	8,88	8,0	77,81	7,68
	4	0,291	9,20	8,3	80,59	16,28
	6	0,295	9,34	8,4	81,83	16,69
	8	0,289	9,13	8,2	79,97	16,63
	10	0,292	9,24	8,3	80,90	16,53
	15	0,287	9,06	8,2	79,35	41,17
	20	0,285	8,99	8,1	78,74	40,61
	25	0,283	8,92	8,0	78,12	40,29
	30	0,279	8,78	7,9	76,88	39,82
					Σ AUC	239,47
					% ED	77,69

LAMPIRAN N

HASIL UJI DISOLUSI TABLET PEMBANDING DOMPERIDONE

Pembanding 1

Rep	t (menit)	Abs.	C (µg/ml)	Wt (mg)	% obat terlepas	AUC (µg menit / ml)
I	0	0	0	0	0	0
	0,5	0,167	4,82	4,3	45,86	1,08
	1	0,204	6,12	5,5	58,30	2,46
	2	0,306	9,72	8,7	92,59	7,13
	4	0,312	9,93	8,9	94,60	17,69
	6	0,322	10,29	9,3	97,97	18,20
	8	0,334	10,71	9,6	102,00	18,90
	10	0,321	10,25	9,2	97,63	18,87
	15	0,327	10,46	9,4	99,65	46,61
	20	0,307	9,76	8,8	92,92	45,50
	25	0,313	9,97	9,0	94,94	44,39
	30	0,319	10,18	9,2	96,96	45,34
					Σ AUC	266,16
					% ED	93,88

Rep	t (menit)	Abs.	C (µg/ml)	Wt (mg)	% obat terlepas	AUC (µg menit / ml)
II	0	0	0	0	0	0
	0,5	0,117	3,05	2,7	28,03	0,69
	1	0,240	7,39	6,7	67,93	2,35
	2	0,277	8,70	7,8	79,93	7,24
	4	0,310	9,86	8,9	90,63	16,71
	6	0,324	10,36	9,3	95,17	18,20
	8	0,328	10,50	9,4	96,47	18,77
	10	0,320	10,22	9,2	93,88	18,64
	15	0,310	9,86	8,9	90,63	45,18
	20	0,326	10,43	9,4	95,82	45,66
	25	0,318	10,15	9,1	93,23	46,29
	30	0,322	10,29	9,3	94,52	45,97
					Σ AUC	265,70
					% ED	90,42
III	0	0	0	0	0	0
	0,5	0,148	4,15	3,7	38,44	0,93
	1	0,227	6,93	6,2	64,31	2,49
	2	0,248	7,67	6,9	71,18	6,57
	4	0,285	8,98	8,1	83,29	14,99
	6	0,327	10,46	9,4	97,04	17,50
	8	0,328	10,50	9,4	97,37	18,87
	10	0,314	10,00	9,0	92,79	18,45
	15	0,325	10,39	9,4	96,39	45,89
	20	0,306	9,72	8,7	90,17	45,26
	25	0,319	10,18	9,2	94,42	44,78
	30	0,326	10,43	9,4	96,72	46,37
					Σ AUC	262,11
					% ED	90,04

Pembanding 2

Rep	t (menit)	Abs.	C (µg/ml)	Wt (mg)	% obat terlepas	AUC (µg menit / ml)
I	0	0	0	0	0	0
	0,5	0,145	4,04	3,6	34,28	0,91
	1	0,284	8,95	8,1	75,91	2,92
	2	0,342	10,99	9,9	93,28	8,97
	4	0,351	11,31	10,2	95,98	20,07
	6	0,358	11,56	10,4	98,08	20,58
	8	0,348	11,20	10,1	95,08	20,49
	10	0,333	10,68	9,6	90,59	19,69
	15	0,343	11,03	9,9	93,58	48,83
	20	0,350	11,28	10,1	95,68	50,18
	25	0,341	10,96	9,9	92,99	50,02
	30	0,342	10,99	9,9	93,28	49,39
					Σ AUC	292,06
					% ED	94,48
II	0	0	0	0	0	0
	0,5	0,196	5,84	5,3	51,91	1,31
	1	0,208	6,26	5,6	55,68	2,72
	2	0,291	9,19	8,3	81,72	6,96
	4	0,352	11,35	10,2	100,86	18,48
	6	0,346	11,13	10,0	98,98	20,23
	8	0,338	10,85	9,8	96,47	19,79
	10	0,336	10,78	9,7	95,84	19,47
	15	0,341	10,96	9,9	97,41	48,91
	20	0,331	10,60	9,5	94,27	48,51
	25	0,334	10,71	9,6	95,21	47,96
	30	0,326	10,43	9,4	92,70	47,56
					Σ AUC	281,91
					% ED	92,82

Rep	t (menit)	Abs.	C (µg/ml)	Wt (mg)	% obat terlepas	AUC (µg menit / ml)
III	0	0	0	0	0	0
	0,5	0,13	3,51	3,2	31,02	0,79
	1	0,241	7,43	6,7	65,64	2,46
	2	0,341	10,96	9,9	96,84	8,27
	4	0,359	11,59	10,4	102,45	20,30
	6	0,348	11,20	10,1	99,02	20,52
	8	0,352	11,35	10,2	100,27	20,30
	10	0,347	11,17	10,1	98,71	20,26
	15	0,337	10,82	9,7	95,59	49,47
	20	0,344	11,06	10,0	97,77	49,23
	25	0,312	9,93	8,9	87,79	47,24
	30	0,331	10,60	9,5	93,72	46,21
					Σ AUC	285,05
					% ED	93,30

LAMPIRAN O

CONTOH PERHITUNGAN

Contoh perhitungan indeks kompresibilitas:

Formula 1 :

Berat gelas = 116,5536 g (W_1)

Berat gelas + granul = 163,9652 g (W_2)

V_1 = 100 mL, V_2 = 79 mL

Bj nyata $= \frac{(W_2 - W_1)}{V_1} = \frac{(163{,}9652 - 116{,}5536)}{100} = 0{,}4741$ g/mL

Bj mampat = $\frac{(W_2 - W_1)}{V_2} = \frac{(163{,}9652 - 116{,}5536)}{79} = 0{,}6001$ g/mL

$Hausner\ Ratio = \frac{bjmampat}{bjnyata} = 1{,}27$

$\%\ Carr's\ Index = \left(1 - \frac{Bj.nyata}{Bj.mampat}\right) x100\% = 21\%$

Contoh perhitungan akurasi & presisi:

Kons. (%)	Massa (mg)	Abs.	Kons. (µg/ml)	Teoritis (µg/ml)	Perolehan Kembali (%)
100	100,7	0,260	8,11	8,11	99,98

Absorbansi = 0,260 → y = 0,0283x + 0,0306

Konsentrasi sampel (x) = 8,10601 ppm ≈ 8,11 ppm

Berat domperidone = 70,5 mg

Berat matriks = 630,0 mg

Berat sampel = 100,7 mg

Konsentrasi teoritis $= \frac{W\ sampel}{(W\ domperidone + W\ matriks)} \times W_{domperidone} \times FP$

$= \frac{100,7}{(70,5+630,0)} \times 70,5 \times 10^3 \times \left(\frac{1}{250} \times \frac{2}{10}\right)$

$= 8,10775$ ppm $\approx 8,11$ ppm

% Perolehan Kembali $= \frac{\text{konsentrasi sampel}}{\text{konsentrasi teoritis}} \times 100\%$

$= \frac{8,10601}{8,10775} \times 100\%$

$= 99,98\%$

% KV $= \frac{SD}{\bar{X}} \times 100\%$

$= \frac{1,42}{100,23} \times 100\%$

$= 1,42\%$

Contoh perhitungan penetapan kadar:

Abs.	Kons. Sampel (µg/ml)	W Tablet Rata-rata (mg)	W Sampel (mg)	Kons. Teoritis (µg/ml)	Kadar (%)
0,253	7,86	99,585	100,6	8,08	97,24

Absorbansi = 0,253 → y = 0,0283x + 0,0306

Konsentrasi sampel (x) = 7,86 ppm

Berat tablet rata-rata = 99,585 g

Berat sampel = 100,6 mg

Berat Domperidone = 10 mg

Konsentrasi teoritis $= \frac{W\ sampel}{W\ tablet\ rata-rata} \times W_{domperidone} \times FP$

$= \frac{100,6}{99,585} \times 10 \times 10^3 \times \left(\frac{1}{250} \times \frac{2}{10}\right)$

= 8,082 ppm

Kadar $= \frac{\text{konsentrasi sampel}}{\text{konsentrasi teoritis}} \times 100\%$

$= \frac{7,86}{8,082} \times 100\%$

= 97,24%

% KV $= \frac{SD}{\overline{X}} \times 100\%$

$= \frac{5,29}{102,55} \times 100\%$

= 5,16%

Contoh perhitungan %obat terlepas:

Formula 1 replikasi I pada t = 30 menit

Absorbansi = 0,247 → y = 0,0283x - 0,0306

Csampel (x) = 7,65 µg/ml

Wt = (900/1000 x konsentrasi sampel)

= (900/1000 x 7,65)

= 6,9 mg

$$\% \text{ Obat Terlepas} = \frac{Wt}{\frac{PK}{100} \times dosis} \times 100\%$$

Formula 1 replikasi I pada t = 30 menit

$$\% \text{ Obat Terlepas} = \frac{6,9}{\frac{97,24}{100} \times 10} \times 100\% = 70,77\%$$

Contoh perhitungan AUC pada disolusi:

Rumus:

Formula 1 replikasi I

tn-1 = 25 menit Wtn-1 = 7,0 mg

tn = 30 menit Wtn = 6,9 mg

$$\text{AUC} = \frac{6,9+7,0}{2} x(30-25) = 34,73$$

Luas □ = 30 x penetapan kadar x dosis

= 30 x 0,9724 x 10 mg

= 291,72629

% ED Formula 1 replikasi I = (∑ AUC / luas□) x 100%

= (251,42/291,72629) x 100%

= 73,84%

LAMPIRAN P

SERTIFIKAT ANALISIS BAHAN

DOMPERIDONE

VASUDHA PHARMA CHEM. LTD

VASUDHA PHARMA CHEM LIMITED
78/A, VENGAL RAO NAGAR, HYDERABAD-38
ANDHRA PRADESH, INDIA
PHONE:+91-40-2381 2046, 2371 1717, FAX: 91-40-2381 1576
E-MAIL: vasudha@vasudhaphrma.com, Website: www.vasudhapharma.com

CERTIFICATE OF ANALYSIS

Name of the product	:	DOMPERIDONE	Page No.	:	1 of 2
Batch Number	:	BDOM/1106090	A.R.No	:	BDOM/11090
Manufacturing Date	:	JUN 2011	Expiry Date	:	MAY 2016
Dispatch Quantity	:	30.0 Kg	Analyzed on	:	18/06/2011
Customer Name/ code	:	PT Taterasa			

S.No	TEST		RESULT	SPECIFICATION
1.0	CHARACTERS			
1.1	Appearance		A white powder	A white or almost white powder.
1.2	Solubility		Complies	Practically insoluble in water; soluble in dimethyl formamide,slightly soluble in alcohol and in methanol
2.0	Identification			
	FIRST IDENTIFICATION			
	A	Melting Point (°)	244.5	244 to248
	B	IR Identification (KBr disc)	Complies	The spectrum obtained with the substance to be examined correspond in position and relative size to those in the spectrum obtained with Domperidone reference standard(Working standard)
	SECOND IDENTIFICATION			
	C	Thin layer chromatography (TLC)	Complies	The principal spot in the chromatogram obtained with the test solution is similar in position and size to the principal spot in the chromatogram obtained with reference solution(a)
	D	Test for non-nitrogen substituted barbiturates	Complies	A violet blue colour and precipitate produces
3.0	TESTS			
3.1	Appearance of solution		Complies	The solution should be clear and not more intensely coloured than reference solution Y_6

PREPARED BY: 21/06/2011 CHECKED BY : 21/06/2011 APPROVED BY: 21/06/2011

RELEASED

Works

I/s. VASUDHA PHARMA CHEM LIMITED, Unit-II, Plot No: 79, J.N.Pharma City, Thanam Village, Parawada Mandalam, Visakhapatnam – 531 021, Andhra Pradesh, India.

VASUDHA PHARMA CHEM. LTD

VASUDHA PHARMA CHEM LIMITED
78/A, VENGAL RAO NAGAR, HYDERABAD-38
ANDHRA PRADESH, INDIA
PHONE:+91-40-2381 2046, 2371 1717, FAX: 91-40-2381 1576
E-MAIL: vasudha@vasudhapharma.com, Website: www.vasudhapharma.com

Name of the product	:	DOMPERIDONE	Page No.	:	2 of 2
Batch Number	:	BDOM/1106090	A.R.No	:	BDOM/11090
Manufacturing Date	:	JUN 2011	Expiry Date	:	MAY 2016
Dispatch Quantity	:	30.0 Kg	Analyzed on	:	18/06/2011
Customer Name/ code	:	PT Taterasa			

S.No	TEST	RESULT	SPECIFICATION
3.2	Heavy metals (ppm)	Less than 20	Not more than 20
3.3	Loss on drying(%,w/w)	0.34	Not more than 0.5
3.4	Sulphated Ash(%,w/w)	0.06	Not more than 0.1
3.5	Assay (By titrimetry, %w/w, on dried basis)	99.53	Not less than 99.0 and Not more than 101.0
3.6	Related substances (By HPLC, %)		
	Impurity-A	0.06	Not more than 0.25
	Impurity-B	Not detected	Not more than 0.25
	Impurity-C	Not detected	Not more than 0.25
	Impurity-D	0.14	Not more than 0.25
	Impurity-E	Not detected	Not more than 0.25
	Impurity-F	Not detected	Not more than 0.25
	Unspecified impurities	Not detected	Not more than 0.10
	Total impurity	0.19	Not more than 0.50

REMARKS: The material complies as per the BP specification.

Sign

PREPARED BY: 21/06/2011 **CHECKED BY :** 21/06/2011 **APPROVED BY:** 21/06/2011

Works

M/s. VASUDHA PHARMA CHEM LIMITED, Unit-II, Plot No: 79, J.N.Pharma City, Thanam Village, Parawada Mandalam, Visakhapatnam – 531 021, Andhra Pradesh, India.

MANITOL



ROQUETTE

I.C 1 EELA CERTIFICATE OF ANALYSIS / COMPLIANCE

PAGE 1

PT SIGNA HUSADA

JALAN DAAN MOGOT KM 17

JAKARTA 11840

INDONESIA

PEARLITOL 160 C

CUSTOMER.... SIGNA HUSADA/INDONES

450001 D

INVOICE..... MD758A1
TONNAGE..... 18.000 KG
CONTRACT.... F55433L
ORDER..... P.O.100002538
BATCH..... E611T
MANUF&TESTED 14 APRIL 2011

EXPIRY DATE.
01 MAY 2016

E.P./U.S.P.

DESCRIPTION

WHITE CRYSTALLINE POWDER
ODOURLESS, SWEET TASTE

MEANING TESTED = ANALYZED
MONITORED = MONITORING PLAN
GUARANTEED = COMPLIANCE DATA

APPEARANCE		CONFORM	TESTED
APPEARANCE IN SOLUTION		CONFORM	TESTED
LOSS ON DRYING	%	0,05	TESTED
INFRA-RED		CONFORM	TESTED
MELTING POINT			
START OF MELTING	DEG	166	TESTED
END OF MELTING	DEG	166	TESTED
SPECIFIC ROTATION(BORATE)	DEG	167	TESTED
SPECIFIC ROT.MOLYBDATE	DEG.	+ 23,6	TESTED
CONDUCTIVITY	DEG	+ 140,1	TESTED
REDUCING SUGARS	MICROS/C	1,0	TESTED
D-MANNITOL BY HPLC	*(USP)	CONFORM	TESTED
	%	99,2	TESTED

ROQUETTE FRERES, 1, RUE DE LA HAUTE LOGE, 62136 LESTREM FRANCE TEL

has an electronic signature

AC-DI-SOL

JRS PHARMA GMBH & CO. KG — THE EXCIPIENT FAMILY

VIVASOL®

Croscarmellose Sodium Ph. Eur., NF, JP

CERTIFICATE OF ANALYSIS

Batch-no.: 3201014100
Re-evaluation date: November 2015
Manufacturing date: November 2011
Manufacturing site: Pirna, Germany

Description	Almost white, very hygroscopic powder; practically insoluble in acetone, ethanol, ether and toluene.

Standards	Specification	Batch Result	Reference
Particle size (retained on air jet sieve)			T226F (MCW)
> 75 µm (200 mesh)	max. 2 %	< 2 %*	
> 45 µm (325 mesh)	max. 10 %	< 10 %*	

Pharmacopoeial test items	Specification	Batch Result	Reference
Identification (A, B, C), (1, 2, 3)	passes	passes*	Ph. Eur., NF, JP
Degree of Substitution	0.60 – 0.85	0.75 *	Ph. Eur., NF, JP
Loss on drying	max. 10.0 %	5.6 %	Ph. Eur., NF, JP
pH	5.0 - 7.0	6.1	Ph. Eur., USP, JP
Content of water-soluble material	1.0 -10.0 %	4.7 %	Ph. Eur., NF, JP
Sulphated ash	14.0 – 28.0 %	passes*	Ph. Eur., JP
Settling volume	10.0 – 30.0 ml	15.0 ml	Ph. Eur., NF, JP
Sodium chloride and Sodium glycolate	max. 0.5 %	< 0.5 %*	Ph. Eur., NF, JP
Heavy metals	max. 10 ppm	< 10 ppm*	T CC 043 (CHP)
Arsenic	max. 2 ppm	< 2 ppm*	T CC 043 (CHP)
Residue of Methanol	max. 1.0 %	< 1.0 %*	T CC 019 (CHP)
Total aerobic microbial count	< 100 CFU / g	< 100 CFU / g*	Ph. Eur., USP
Fungi / molds and yeasts	< 20 CFU / g	< 20 CFU / g*	Ph. Eur., USP
E. coli, Pseudomonas aeruginosa	absent in 10 g	absent*	Ph. Eur., USP
Staph. aureus, Salmonella spec.	absent in 10 g	absent*	Ph. Eur., USP

* Results reported are expected results based on periodic testing.

The batch described by this certificate meets the requirements of Ph. Eur., NF and JP monographs for "Croscarmellose Sodium" current edition. It is released on the basis of the results ascertained.

The raw materials, manufacturing process, and product do not contain any of the solvents listed in the Residual Solvents (Ph. Eur.<5.4>, USP<467>) except for Methanol limited to max. 1.0%.

This product may contain raw materials derived from unauthorized genetically modified cotton and is not suitable for the production or marketing of food or dietary supplements in the EC.

Storage recommendation: **Protect from excessive heat and moisture.**
Keep containers closed.

November 25, 2011
AB: 21142739
VSOL P09

Mathias Winkelmann
QUALITY CONTROL
CHP Carbohydrate Pirna

Worldwide headquarters
JRS PHARMA GMBH & CO. KG
73494 Rosenberg (Gaumang) · Holzmühle 1
Phone: + 49 (0) 7967 / 152 312
Fax: + 49 (0) 7967 / 152 345
info@jrspharma.de · www.jrspharma.de · www.jrs.de
Customer Service: + 49 (0) 7967 / 152 312

USA + Canada
JRS PHARMA LP
2981 Route 22, Suite 1 · Patterson, NY 12563-2359, USA
Toll-free (USA): + 1 (800) 431 2457
Phone: + 1 (845) 878 3414 · Fax: + 1 (845) 878 3484
info@jrspharma.com · www.jrspharma.com
Customer Service: + 1 (845) 878 3414

LAMPIRAN Q

TABEL UJI F

TABEL DISTRIBUSI F UNTUK 5% DAN 1%

Baris atas untuk taraf signifikan 5%
Baris bawah untuk taraf signifikan 1%

V_2 = dk penyebut	V_1 = dk pembilang																						
	1	2	3	4	5	6	7	8	9	10	11	12	14	16	20	24	30	40	50	75	100	200	500	∞
1	161	200	216	225	230	234	237	239	241	242	243	244	245	246	248	249	250	251	252	253	253	254	254	254
	4052	4999	5403	5625	5764	5859	5928	5961	6022	6056	6082	6106	6142	61,69	6208	6234	6258	6286	6302	6323	6334	6352	6361	6366
2	18,51	19,00	19,16	19,25	19,30	19,33	19,36	19,37	19,38	19,39	19,40	19,41	19,42	19,43	19,44	19,45	19,46	19,47	19,47	19,48	19,49	19,49	19,50	19,50
	98,49	99,01	99,17	99,25	99,30	99,33	99,34	99,36	97,38	99,40	99,41	99,42	99,43	99,44	99,45	99,46	99,47	99,48	99,48	99,49	99,49	99,49	99,50	99,50
3	10,13	9,55	9,28	9,12	9,01	8,94	8,88	8,84	8,81	8,78	8,76	8,74	8,71	8,69	8,66	8,64	8,62	8,60	8,58	8,57	8,56	8,54	8,54	8,53
	34,12	30,81	29,46	28,71	28,24	27,91	27,67	27,49	27,34	27,23	27,13	27,05	26,92	26,83	26,69	26,60	26,50	26,41	26,30	26,27	26,23	26,18	26,14	26,12
4	7,71	6,94	6,59	6,39	6,26	6,16	6,09	6,04	6,00	5,96	5,93	5,91	5,87	5,84	5,80	5,77	5,74	5,71	5,70	5,68	5,66	5,65	5,64	5,63
	21,20	18,00	16,69	15,98	15,52	15,21	14,98	14,80	14,66	14,54	14,45	14,37	14,24	14,15	14,02	13,93	13,83	13,74	13,69	13,61	13,57	13,52	13,48	13,46
5	6,61	5,79	5,41	5,19	5,05	4,95	4,88	4,82	4,78	4,74	4,70	4,68	4,64	4,60	4,56	4,53	4,50	4,46	4,44	4,42	4,40	4,38	4,37	4,36
	16,26	13,27	12,06	11,39	10,97	10,67	10,45	10,27	10,15	10,05	9,96	9,89	9,77	9,68	9,55	9,47	9,38	9,29	9,24	9,17	9,13	9,07	9,04	9,02
6	5,99	5,14	4,76	4,53	4,39	4,28	4,21	4,15	4,10	4,06	4,03	4,00	3,96	3,92	3,87	3,84	3,81	3,77	3,75	3,72	3,71	3,69	3,68	3,67
	13,74	10,92	9,78	9,15	8,75	8,47	8,26	8,10	7,98	7,87	7,79	7,72	7,60	7,52	7,39	7,31	7,23	7,14	7,09	7,02	6,99	6,94	6,90	6,88
7	5,59	4,74	4,35	4,12	3,97	3,87	3,79	3,73	3,68	3,63	3,60	3,57	3,52	3,49	3,44	3,41	3,38	3,34	3,32	3,29	3,28	3,25	3,24	3,23
	12,25	9,55	8,45	7,85	7,46	7,19	7,00	6,84	6,71	6,62	6,54	6,47	6,35	6,27	6,15	6,07	5,98	5,90	5,85	5,78	5,75	5,70	5,67	5,65
8	5,32	4,46	4,07	3,84	3,69	3,58	3,50	3,44	3,39	3,34	3,31	3,28	3,23	3,20	3,15	3,12	3,08	3,05	3,03	3,00	2,98	2,96	2,94	2,93
	11,26	8,65	7,59	7,01	6,63	6,37	6,19	6,03	5,91	5,82	5,74	5,67	5,56	5,48	5,36	5,28	5,20	5,11	5,06	5,00	4,96	4,91	4,88	4,86
9	5,12	4,26	3,86	3,63	3,48	3,37	3,29	3,23	3,18	3,13	3,10	3,07	3,02	2,98	2,93	2,90	2,86	2,82	2,80	2,77	2,76	2,73	2,72	2,71
	10,56	8,02	6,99	6,42	6,06	5,80	5,62	5,47	5,35	5,26	5,18	5,11	5,00	4,92	4,80	4,73	4,61	4,56	4,51	4,45	4,41	4,36	4,33	4,34

V_2 = dk penyebut	V_1 = dk pembilang																						
	1	2	3	4	5	6	7	8	9	10	11	12	14	16	20	24	30	40	50	75	100	200	500	∞
10	4,96	4,10	3,71	3,48	3,33	3,22	3,14	3,07	3,02	2,97	2,94	2,91	2,86	2,82	2,77	2,74	2,70	2,67	2,64	2,61	2,59	2,56	2,55	2,54
	10,04	7,56	6,55	5,99	5,64	5,39	5,21	5,06	4,95	4,85	4,78	4,71	4,60	4,52	4,41	4,33	4,25	4,17	4,12	4,05	4,01	3,96	3,93	3,91
11	4,84	3,98	3,59	3,36	3,20	3,09	3,01	2,95	2,90	2,86	2,82	2,79	2,74	2,70	2,65	2,61	2,57	2,53	2,50	2,47	2,45	2,42	2,41	2,40
	9,65	7,20	6,22	5,67	5,32	5,07	4,88	4,74	4,63	4,54	4,46	4,40	4,29	4,21	4,10	4,02	3,94	3,86	3,80	3,74	3,70	3,66	3,62	3,60
12	4,75	3,88	3,49	3,26	3,11	3,00	2,92	2,85	2,80	2,76	2,72	2,69	2,64	2,60	2,54	2,50	2,46	2,42	2,40	2,36	2,35	2,32	2,31	2,30
	9,33	6,93	5,95	5,41	5,06	4,82	4,65	4,50	4,39	4,30	4,22	4,16	4,05	3,98	3,86	3,78	3,70	3,61	3,56	3,49	3,46	3,41	3,38	3,36
13	4,67	3,80	3,41	3,18	3,02	2,92	2,84	2,77	2,72	2,67	2,63	2,60	2,55	2,51	2,46	2,42	2,38	2,34	2,32	2,28	2,26	2,24	2,22	2,21
	9,07	6,70	5,74	5,20	4,86	4,62	4,44	4,30	4,19	4,10	4,02	3,96	3,85	3,78	3,67	3,59	3,51	3,42	3,37	3,30	3,27	3,21	3,18	3,16
14	4,60	3,74	3,34	3,11	2,96	2,85	2,77	2,70	2,65	2,60	2,56	2,53	2,48	2,44	2,39	2,35	2,31	2,27	2,24	2,21	2,19	2,16	2,14	2,13
	8,86	6,51	5,56	5,03	4,69	4,46	4,28	4,14	4,03	3,94	3,86	3,80	3,70	3,62	3,51	3,43	3,34	3,26	3,21	3,14	3,11	3,06	3,02	3,00
15	4,54	3,68	3,29	3,06	2,90	2,79	2,70	2,64	2,59	2,55	2,51	2,48	2,43	2,39	2,33	2,29	2,25	2,21	2,18	2,15	2,12	2,10	2,08	2,07
	8,68	6,36	5,42	4,89	4,56	4,32	4,14	4,00	3,89	3,80	3,73	3,67	3,56	3,48	3,36	3,29	3,20	3,12	3,07	3,00	2,97	2,92	2,89	2,87
16	4,49	3,63	3,24	3,01	2,85	2,74	2,66	2,59	2,54	2,49	2,45	2,42	2,37	2,33	2,28	2,24	2,20	2,16	2,13	2,09	2,07	2,04	2,02	2,01
	8,53	6,23	5,29	4,77	4,44	4,20	4,03	3,89	3,78	3,69	3,61	3,55	3,45	3,37	3,25	3,18	3,10	3,01	2,96	2,89	2,86	2,80	2,77	2,75
17	4,45	3,59	3,20	2,96	2,81	2,70	2,62	2,55	2,50	2,45	2,41	2,38	2,33	2,29	2,23	2,19	2,15	2,11	2,08	2,04	2,02	1,99	1,97	1,96
	8,40	6,11	5,18	4,67	4,34	4,10	3,93	3,79	3,68	3,59	3,52	3,45	3,35	3,27	3,16	3,08	3,00	2,92	2,86	2,79	2,76	2,70	2,67	2,65
18	4,41	3,55	3,16	2,93	2,77	2,66	2,58	2,51	2,46	2,41	2,37	2,34	2,29	2,25	2,19	2,15	2,11	2,07	2,04	2,00	1,98	1,95	1,93	1,92
	8,28	6,01	5,09	4,58	4,25	4,01	3,85	3,71	3,60	3,51	3,44	3,37	3,27	3,19	3,07	3,00	2,91	2,83	2,78	2,71	2,68	2,62	2,59	2,57
19	4,38	3,52	3,13	2,90	2,74	2,63	2,55	2,48	2,43	2,38	2,34	2,31	2,26	2,21	2,15	2,11	2,07	2,02	2,00	1,96	1,94	1,91	1,90	1,88
	8,18	5,93	5,01	4,50	4,17	3,94	3,77	3,63	3,52	3,43	3,36	3,30	3,19	3,12	3,00	2,92	2,84	2,76	2,70	2,63	2,60	2,54	2,51	2,49
20	4,35	3,49	3,10	2,87	2,71	2,60	2,52	2,45	2,40	2,35	2,31	2,26	2,23	2,18	2,12	2,08	2,04	1,99	1,96	1,92	1,90	1,87	1,85	1,84
	8,10	5,85	4,94	4,43	4,10	3,87	3,71	3,56	3,45	3,37	3,30	3,23	3,13	3,05	2,94	2,86	2,77	2,69	2,63	2,56	2,53	2,47	2,44	2,42
21	4,32	3,47	3,07	2,84	2,68	2,57	2,49	2,42	2,37	2,32	2,28	2,25	2,20	2,15	2,09	2,05	2,00	1,96	1,93	1,89	1,87	1,84	1,82	1,81
	8,02	5,78	4,87	4,37	4,04	3,81	3,65	3,51	3,40	3,31	3,24	3,17	3,07	2,99	2,88	2,80	2,72	2,63	2,58	2,51	2,47	2,42	2,38	2,36
22	4,30	3,44	3,05	2,82	2,66	2,55	2,47	2,40	2,35	2,30	2,26	2,23	2,18	2,13	2,07	2,03	1,98	1,93	1,91	1,87	1,84	1,81	1,80	1,78
	7,94	5,72	4,82	4,31	3,99	3,76	3,59	3,45	3,35	3,26	3,18	3,12	3,02	2,94	2,83	2,75	2,67	2,58	2,53	2,46	2,42	2,37	2,33	2,31
23	4,28	3,42	3,03	2,80	2,64	2,53	2,45	2,38	2,32	2,28	2,24	2,20	2,14	2,10	2,04	2,00	1,96	1,91	1,88	1,84	1,82	1,79	1,77	1,76
	7,88	5,66	4,76	4,26	3,94	3,71	3,54	3,41	3,30	3,21	3,14	3,07	2,97	2,89	2,78	2,70	2,62	2,53	2,48	2,41	2,37	2,32	2,28	2,26

LAMPIRAN R

TABEL UJI R

DEGREES OF FREEDOM (DF)	5 PERCENT	1 PERCENT	DEGREES OF FREEDOM (DF)	5 PERCENT	1 PERCENT
1	.997	1.000	24	.388	.496
2	.950	.990	25	.381	.487
3	.878	.959	26	.374	.478
4	.811	.917	27	.367	.470
5	.754	.874	28	.361	.463
6	.707	.834	29	.355	.456
7	.666	.798	30	.349	.449
8	.632	.765	35	.325	.418
9	.602	.735	40	.304	.393
10	.576	.708	48	.288	.372
11	.553	.684	50	.273	.354
12	.532	.661	60	.250	.325
13	.514	.641	70	.232	.302
14	.497	.623	80	.217	.283
15	.482	.606	90	.205	.267
16	.468	.590	100	.195	.254
17	.456	.575	125	.174	.228
18	.444	.561	150	.159	.208
19	.433	.549	200	.138	.181
20	.423	.537	300	.113	.148
21	.413	.526	400	.098	.128
22	.404	.515	500	.088	.115
23	.396	.505	1000	.062	.081

Dikutip dari: Soedigdo & Soedigdo (1977)

LAMPIRAN S

TABEL UJI HSD (0,05)

d.k. \ k	2	3	4	5	6	7	8	9	10	11
5	3.64	4.60	5.22	5.67	6.03	6.33	6.58	6.80	6.99	7.17
6	3.46	4.34	4.90	5.30	5.63	5.90	6.12	6.32	6.49	6.65
7	3.34	4.16	4.68	5.06	5.36	5.61	5.82	6.00	6.16	6.30
8	3.26	4.04	4.53	4.89	5.17	5.40	5.60	5.77	5.92	6.05
9	3.20	3.95	4.41	4.76	5.02	5.24	5.43	5.59	5.74	5.87
10	3.15	3.88	4.33	4.65	4.91	5.12	5.30	5.46	5.60	5.72
11	3.11	3.82	4.26	4.57	4.82	5.03	5.20	5.35	5.49	5.61
12	3.08	3.77	4.20	4.51	4.75	4.95	5.12	5.27	5.39	5.51
13	3.06	3.73	4.15	4.45	4.69	4.88	5.05	5.19	5.32	5.43
14	3.03	3.70	4.11	4.41	4.64	4.83	4.99	5.13	5.25	5.36
15	3.01	3.67	4.08	4.37	4.59	4.78	4.94	5.08	5.20	5.31
16	3.00	3.65	4.05	4.33	4.56	4.74	4.90	5.03	5.15	5.26
17	2.98	3.63	4.02	4.30	4.52	4.71	4.86	4 99	5.11	5.21
18	2.97	3.61	4.00	4.28	4.49	4.67	4.82	4.96	5.07	5.17
19	2.96	3.59	3.98	4.25	4.47	4.65	4.79	4.92	5.04	5.14
20	2.95	3.58	3.96	4.23	4.45	4.62	4.77	4.90	5.01	5.11
24	2.92	3.53	3.90	4.17	4.37	4.54	4.68	4.81	4.92	5.01
30	2.89	3.49	3.85	4.10	4.30	4.46	4.60	4.72	4.82	4.92
40	2.86	3.44	3.79	4.04	4.23	4.39	4.52	4.63	4.73	4.82
60	2.83	3.40	3.74	3.98	4.16	4.31	4.44	4.55	4.65	4.73
120	2.80	3.36	3.68	3.92	4.10	4.24	4.36	4.47	4.56	4.64
∞	2.77	3.31	3.63	3.86	4.03	4.17	4.29	4.39	4.47	4.55

Catatan kaki: Dari *Annals of mathematical statistics.* Diulang cetak seizin penerbit, The Institute of Mathematical Statistics.

Sumber: Schefler (1987).

LAMPIRAN T

TABEL UJI T

v	α				
	0.10	0.05	0.025	0.01	0.005
1	3.078	6.314	12.706	31.821	63.657
2	1.886	2.920	4.303	6.965	9.925
3	1.638	2.353	3.182	4.451	5.841
4	1.533	2.132	2.776	3.747	4.604
5	1.476	2.015	2.561	3.365	4.012
6	1.440	1.943	2.447	3.143	3.707
7	1.415	1.895	2.365	2.998	3.499
8	1.397	1.860	2.306	2.896	3.355
9	1.383	1.833	2.262	2.821	3.250
10	1.372	1.812	2.228	2.764	3.169
11	1.363	1.796	2.201	2.718	3.106
12	1.356	1.782	2.179	2.681	3.055
13	1.350	1.771	2.160	2.650	3.012
14	1.345	1.761	2.145	2.624	2.977
15	1.341	1.753	2.131	2.602	2.947
16	1.337	1.746	2.120	2.583	2.921
17	1.333	1.740	2.110	2.567	2.898
18	1.330	1.734	2.101	2.552	2.878
19	1.328	1.729	2.093	2.539	2.861
20	1.325	1.725	2.086	2.528	2.845
21	1.323	1.721	2.080	2.518	2.831
22	1.321	1.717	2.074	2.508	2.819
23	1.319	1.714	2.069	2.500	2.807
24	1.318	1.711	2.064	2.492	2.797
25	1.316	1.708	2.060	2.485	2.787
26	1.315	1.706	2.056	2.479	2.779
27	1.314	1.703	2.052	2.473	2.771
28	1.313	1.701	2.048	2.467	2.763
29	1.311	1.699	2.045	2.462	2.756
inf.	1.282	1.645	1.960	2.326	2.576

Sumber : Ronald E. Walpole (1995) : Pengantar Statistika.

LAMPIRAN U

HASIL UJI STATISTIK KEKERASAN ODT DOMPERIDONE

Descriptives

kekerasan

	N	Mean	Std. Devia-tion	Std. Error	95% Confidence Interval for Mean		Min	Max
					Lower Bound	Upper Bound		
1	3	3.0133	.20817	.12019	2.4962	3.5304	2.78	3.18
2	3	2.8767	.42477	.24524	1.8215	3.9319	2.42	3.26
3	3	3.2167	.06351	.03667	3.0589	3.3744	3.18	3.29
4	3	2.7700	.35086	.20257	1.8984	3.6416	2.38	3.06
Total	12	2.9692	.30690	.08860	2.7742	3.1642	2.38	3.29

Test of Homogeneity of Variances

kekerasan

Levene Statistic	df1	df2	Sig.
2.214	3	8	.164

ANOVA

kekerasan

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	.334	3	.111	1.270	.348
Within Groups	.702	8	.088		
Total	1.036	11			

Keterangan:

Ho diterima jika F_{hitung} (1,270) < $F_{tabel\ 0,05\ (3,8)}$ (4,07), berarti rata-rata kekerasan tablet dari keempat formula menunjukkan bahwa tidak ada perbedaan yang signifikan antar formula.

LAMPIRAN V

HASIL UJI STATISTIK KERAPUHAN ODT DOMPERIDONE

Descriptives

kerapuhan

	N	Mean	Std. Devia-tion	Std. Error	95% Confidence Interval for Mean		Min	Max
					Lower Bound	Upper Bound		
1	3	.8300	.59758	.34501	-.6545	2.3145	.48	1.52
2	3	.8167	.58321	.33672	-.6321	2.2654	.47	1.49
3	3	.3367	.29195	.16856	-.3886	1.0619	.00	.52
4	3	.8100	.58924	.34020	-.6537	2.2737	.45	1.49
Total	12	.6983	.50301	.14521	.3787	1.0179	.00	1.52

Test of Homogeneity of Variances

kerapuhan

Levene Statistic	df1	df2	Sig.
1.256	3	8	.353

ANOVA

kerapuhan

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	.524	3	.175	.618	.622
Within Groups	2.259	8	.282		
Total	2.783	11			

Keterangan:

Ho diterima jika F_{hitung} (0,618) < $F_{tabel\ 0,05\ (3,8)}$ (4,07), berarti rata-rata kerapuhan tablet dari keempat formula menunjukkan bahwa tidak ada perbedaan yang signifikan antar formula.

LAMPIRAN W

HASIL UJI STATISTIK WAKTU HANCUR ODT DOMPERIDONE

Descriptives

waktu hancur

	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Min	Max
					Lower Bound	Upper Bound		
1	3	52.4667	20.38660	11.77021	1.8236	103.1098	40.20	76.00
2	3	32.7333	2.80951	1.62207	25.7541	39.7125	29.80	35.40
3	3	126.7333	27.54294	15.90192	58.3129	195.1538	95.80	148.60
4	3	58.4000	16.14559	9.32166	18.2921	98.5079	40.00	70.20
Total	12	67.5833	40.41138	11.66576	41.9072	93.2595	29.80	148.60

Test of Homogeneity of Variances

waktu hancur

Levene Statistic	df1	df2	Sig.
3.669	3	8	.063

ANOVA

waktu hancur

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	15078.277	3	5026.092	13.934	.002
Within Groups	2885.600	8	360.700		
Total	17963.877	11			

Keterangan:

Ho ditolak jika F_{hitung} (13,934) > $F_{tabel\ 0,05\ (3,8)}$ (4,07), berarti rata-rata waktu hancur tablet dari keempat formula menunjukkan bahwa ada perbedaan yang signifikan antar formula.

Multiple Comparisons

waktu hancur
HSD

(I) formula	(J) formula	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
1	2	19.73333	15.50699	.239	-16.0258	55.4925
	3	-74.26667*	15.50699	.001	-110.0258	-38.5075
	4	-5.93333	15.50699	.712	-41.6925	29.8258
2	1	-19.73333	15.50699	.239	-55.4925	16.0258
	3	-94.00000*	15.50699	.000	-129.7592	-58.2408
	4	-25.66667	15.50699	.136	-61.4258	10.0925
3	1	74.26667*	15.50699	.001	38.5075	110.0258
	2	94.00000*	15.50699	.000	58.2408	129.7592
	4	68.33333*	15.50699	.002	32.5742	104.0925
4	1	5.93333	15.50699	.712	-29.8258	41.6925
	2	25.66667	15.50699	.136	-10.0925	61.4258
	3	-68.33333*	15.50699	.002	-104.0925	-32.5742

*. The mean difference is significant at the 0.05 level.

Keterangan:

Hasil uji HSD dari keempat formula, diperoleh nilai sig. < α (0,05) sehingga Ho ditolak (*), berarti rata-rata waktu hancur tablet dari keempat formula menunjukkan bahwa ada perbedaan yang signifikan antar formula, yaitu formula 1 menunjukkan perbedaan yang signifikan terhadap formula 3; formula 2 menunjukkan perbedaan yang signifikan terhadap formula 3; formula 3 menunjukkan perbedaan yang signifikan terhadap formula 4, sedangkan formula 1 tidak menunjukkan perbedaan yang signifikan terhadap formula 2 dan formula 4.

LAMPIRAN X

HASIL UJI STATISTIK WAKTU PEMBASAHAN ODT DOMPERIDONE

Descriptives

waktu pembasahan

	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Min	Max
					Lower Bound	Upper Bound		
1	3	35.1133	4.00308	2.31118	25.1691	45.0575	30.50	37.67
2	3	73.2233	19.44578	11.22703	24.9173	121.5293	52.67	91.33
3	3	65.1100	7.62071	4.39982	46.1791	84.0409	56.83	71.83
4	3	116.0000	46.53986	26.86980	.3886	231.6114	75.83	167.00
Total	12	72.3617	37.26028	10.75612	48.6876	96.0357	30.50	167.00

Test of Homogeneity of Variances

waktu pembasahan

Levene Statistic	df1	df2	Sig.
4.359	3	8	.043

ANOVA

waktu pembasahan

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	10035.215	3	3345.072	5.110	.029
Within Groups	5236.395	8	654.549		
Total	15271.609	11			

Keterangan:

Ho ditolak jika F_{hitung} (5,110) > $F_{tabel\ 0,05\ (3,8)}$ (4,07), berarti rata-rata waktu pembasahan dari keempat formula menunjukkan bahwa ada perbedaan yang signifikan antar formula.

Multiple Comparisons

waktu pembasahan

HSD

(I) formula	(J) formula	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
1	2	-38.11000	20.88938	.106	-86.2810	10.0610
	3	-29.99667	20.88938	.189	-78.1677	18.1743
	4	-80.88667*	20.88938	.005	-129.0577	-32.7157
2	1	38.11000	20.88938	.106	-10.0610	86.2810
	3	8.11333	20.88938	.708	-40.0577	56.2843
	4	-42.77667	20.88938	.075	-90.9477	5.3943
3	1	29.99667	20.88938	.189	-18.1743	78.1677
	2	-8.11333	20.88938	.708	-56.2843	40.0577
	4	-50.89000*	20.88938	.041	-99.0610	-2.7190
4	1	80.88667*	20.88938	.005	32.7157	129.0577
	2	42.77667	20.88938	.075	-5.3943	90.9477
	3	50.89000*	20.88938	.041	2.7190	99.0610

*. The mean difference is significant at the 0.05 level.

Keterangan:

Hasil uji HSD dari keempat formula, diperoleh nilai sig. < α (0,05) sehingga Ho ditolak (*), berarti rata-rata waktu pembasahan dari keempat formula menunjukkan bahwa ada perbedaan yang signifikan antar formula, yaitu formula 1 menunjukkan perbedaan yang signifikan terhadap formula 4; formula 3 menunjukkan perbedaan yang signifikan terhadap formula 4, sedangkan formula 1 tidak menunjukkan perbedaan yang signifikan terhadap formula 2 dan formula 3; dan formula 4 tidak menunjukkan perbedaan yang signifikan terhadap formula 2.

LAMPIRAN Y

HASIL UJI STATISTIK RASIO ABSORBSI AIR ODT DOMPERIDONE

Descriptives

rasio absorpsi air

	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Min	Max
					Lower Bound	Upper Bound		
1	3	32.4933	5.39520	3.11492	19.0909	45.8957	27.24	38.02
2	3	56.6933	4.10919	2.37244	46.4855	66.9011	51.95	59.17
3	3	28.8500	7.76203	4.48141	9.5681	48.1319	23.96	37.80
4	3	50.7333	7.24165	4.18097	32.7441	68.7226	44.15	58.49
Total	12	42.1925	13.42764	3.87623	33.6610	50.7240	23.96	59.17

Test of Homogeneity of Variances

rasio absorpsi air

Levene Statistic	df1	df2	Sig.
.678	3	8	.589

ANOVA

rasio absorpsi air

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	1665.948	3	555.316	13.998	.002
Within Groups	317.368	8	39.671		
Total	1983.317	11			

Keterangan:

Ho ditolak jika F_{hitung} (13,998) > $F_{tabel\ 0,05\ (3,8)}$ (4,07), berarti rata-rata rasio absorpsi air dari keempat formula menunjukkan bahwa ada perbedaan yang signifikan antar formula.

Multiple Comparisons

rasio absorpsi air

HSD

(I) formula	(J) formula	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
1	2	-24.20000*	5.14270	.002	-36.0591	-12.3409
	3	3.64333	5.14270	.499	-8.2158	15.5024
	4	-18.24000*	5.14270	.008	-30.0991	-6.3809
2	1	24.20000*	5.14270	.002	12.3409	36.0591
	3	27.84333*	5.14270	.001	15.9842	39.7024
	4	5.96000	5.14270	.280	-5.8991	17.8191
3	1	-3.64333	5.14270	.499	-15.5024	8.2158
	2	-27.84333*	5.14270	.001	-39.7024	-15.9842
	4	-21.88333*	5.14270	.003	-33.7424	-10.0242
4	1	18.24000*	5.14270	.008	6.3809	30.0991
	2	-5.96000	5.14270	.280	-17.8191	5.8991
	3	21.88333*	5.14270	.003	10.0242	33.7424

*. The mean difference is significant at the 0.05 level.

Keterangan:

Hasil uji HSD dari keempat formula, diperoleh nilai sig. < α (0,05) sehingga Ho ditolak (*), berarti rata-rata rasio absorpsi air dari keempat formula menunjukkan bahwa ada perbedaan yang signifikan antar formula, yaitu formula 1 menunjukkan perbedaan yang signifikan terhadap formula 2 dan formula 4; formula 2 menunjukkan perbedaan yang signifikan terhadap formula 3; dan formula 3 menunjukkan perbedaan yang signifikan terhadap formula 4, sedangkan formula 1 tidak menunjukkan perbedaan yang signifikan terhadap formula 3; formula 2 juga tidak menunjukkan perbedaan yang signifikan terhadap formula 4.

LAMPIRAN Z

HASIL UJI STATISTIK PERSEN OBAT TERLEPAS PADA T=30 MENIT

Descriptives

t30 menit

	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Min	Max
					Lower Bound	Upper Bound		
1	3	76.2800	4.83116	2.78927	64.2787	88.2813	70.77	79.79
2	3	83.2433	6.36678	3.67586	67.4274	99.0593	75.91	87.36
3	3	81.3333	5.03339	2.90603	68.8297	93.8370	77.97	87.12
4	3	79.0133	3.63459	2.09843	69.9845	88.0422	76.88	83.21
pembanding 1	3	96.0667	1.34482	.77643	92.7260	99.4074	94.52	96.96
pembanding 2	3	93.2333	.51160	.29537	91.9625	94.5042	92.70	93.72
Total	18	84.8617	8.27698	1.95090	80.7456	88.9777	70.77	96.96

Test of Homogeneity of Variances

t30 menit

Levene Statistic	df1	df2	Sig.
4.401	5	12	.017

ANOVA

t30 menit

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	955.659	5	191.132	10.975	.000
Within Groups	208.983	12	17.415		
Total	1164.642	17			

Keterangan:

Ho ditolak jika F_{hitung} (10,975) > $F_{tabel\ 0,05\ (3,8)}$ (4,07), berarti rata-rata persen obat terlepas pada t=30 menit dari keempat formula dan pembanding menunjukkan bahwa ada perbedaan yang signifikan antar formula.

Multiple Comparisons

t30 menit

HSD

(I) formula	(J) formula	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
1	2	-6.96333	3.40737	.064	-14.3874	.4607
	3	-5.05333	3.40737	.164	-12.4774	2.3707
	4	-2.73333	3.40737	.438	-10.1574	4.6907
	pembanding 1	-19.78667*	3.40737	.000	-27.2107	-12.3626
	pembanding 2	-16.95333*	3.40737	.000	-24.3774	-9.5293
2	1	6.96333	3.40737	.064	-.4607	14.3874
	3	1.91000	3.40737	.585	-5.5140	9.3340
	4	4.23000	3.40737	.238	-3.1940	11.6540
	pembanding 1	-12.82333*	3.40737	.003	-20.2474	-5.3993
	pembanding 2	-9.99000*	3.40737	.013	-17.4140	-2.5660
3	1	5.05333	3.40737	.164	-2.3707	12.4774
	2	-1.91000	3.40737	.585	-9.3340	5.5140
	4	2.32000	3.40737	.509	-5.1040	9.7440
	pembanding 1	-14.73333*	3.40737	.001	-22.1574	-7.3093
	pembanding 2	-11.90000*	3.40737	.004	-19.3240	-4.4760
4	1	2.73333	3.40737	.438	-4.6907	10.1574
	2	-4.23000	3.40737	.238	-11.6540	3.1940
	3	-2.32000	3.40737	.509	-9.7440	5.1040
	pembanding 1	-17.05333*	3.40737	.000	-24.4774	-9.6293
	pembanding 2	-14.22000*	3.40737	.001	-21.6440	-6.7960
Pemban -ding 1	1	19.78667*	3.40737	.000	12.3626	27.2107
	2	12.82333*	3.40737	.003	5.3993	20.2474
	3	14.73333*	3.40737	.001	7.3093	22.1574
	4	17.05333*	3.40737	.000	9.6293	24.4774
	pembanding 2	2.83333	3.40737	.422	-4.5907	10.2574
Pemban -ding 2	1	16.95333*	3.40737	.000	9.5293	24.3774
	2	9.99000*	3.40737	.013	2.5660	17.4140
	3	11.90000*	3.40737	.004	4.4760	19.3240
	4	14.22000*	3.40737	.001	6.7960	21.6440
	pembanding 1	-2.83333	3.40737	.422	-10.2574	4.5907

*. The mean difference is significant at the 0.05 level.

Keterangan:

Hasil uji HSD dari keempat formula, diperoleh nilai sig. < α (0,05) sehingga Ho ditolak (*), berarti rata-rata persen obat terlepas pada t=30 menit dari keempat formula dan kedua pembanding menunjukkan bahwa ada perbedaan yang signifikan antar formula, yaitu formula 1 menunjukkan perbedaan yang signifikan terhadap pembanding 1 dan pembanding 2; formula 2 menunjukkan perbedaan yang signifikan terhadap pembanding 1 dan pembanding 2; formula 3 menunjukkan perbedaan yang signifikan terhadap pembanding 1 dan pembanding 2; dan formula 4 menunjukkan perbedaan yang signifikan terhadap pembanding 1 dan pembanding 2, sedangkan formula 1 tidak menunjukkan perbedaan yang signifikan terhadap formula 2, formula 3, dan formula 4; formula 2 juga tidak menunjukkan perbedaan yang signifikan terhadap formula 3 dan formula 4; formula 3 juga tidak menunjukkan perbedaan yang signifikan terhadap formula 4.

LAMPIRAN AA

HASIL UJI STATISTIK PERSEN EFISIENSI DISOLUSI

Descriptives

% ED

	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Min	Max
					Lower Bound	Upper Bound		
1	3	77.0633	2.79160	1.61173	70.1286	83.9981	73.84	78.70
2	3	80.8733	4.70300	2.71528	69.1904	92.5562	76.02	85.41
3	3	80.0100	5.19962	3.00200	67.0934	92.9266	75.16	85.50
4	3	79.3467	3.49323	2.01682	70.6690	88.0243	76.99	83.36
pembanding 1	3	91.4467	2.11588	1.22160	86.1905	96.7028	90.04	93.88
pembanding 2	3	93.5333	.85424	.49320	91.4113	95.6554	92.82	94.48
Total	18	83.7122	7.16460	1.68871	80.1494	87.2751	73.84	94.48

Test of Homogeneity of Variances

% ED

Levene Statistic	df1	df2	Sig.
1.349	5	12	.309

ANOVA

% ED

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	723.922	5	144.784	11.683	.000
Within Groups	148.713	12	12.393		
Total	872.636	17			

Keterangan:

Ho ditolak jika F_{hitung} (11,683) > $F_{tabel\ 0,05\ (3,8)}$ (4,07), berarti rata-rata % ED dari keempat formula dan pembanding menunjukkan bahwa ada perbedaan yang signifikan antar formula.

Multiple Comparisons

% ED
HSD

(I) formula	(J) formula	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
1	2	-3.81000	2.87434	.210	-10.0727	2.4527
	3	-2.94667	2.87434	.326	-9.2093	3.3160
	4	-2.28333	2.87434	.442	-8.5460	3.9793
	pembanding 1	-14.38333*	2.87434	.000	-20.6460	-8.1207
	pembanding 2	-16.47000*	2.87434	.000	-22.7327	-10.2073
2	1	3.81000	2.87434	.210	-2.4527	10.0727
	3	.86333	2.87434	.769	-5.3993	7.1260
	4	1.52667	2.87434	.605	-4.7360	7.7893
	pembanding 1	-10.57333*	2.87434	.003	-16.8360	-4.3107
	pembanding 2	-12.66000*	2.87434	.001	-18.9227	-6.3973
3	1	2.94667	2.87434	.326	-3.3160	9.2093
	2	-.86333	2.87434	.769	-7.1260	5.3993
	4	.66333	2.87434	.821	-5.5993	6.9260
	pembanding 1	-11.43667*	2.87434	.002	-17.6993	-5.1740
	pembanding 2	-13.52333*	2.87434	.001	-19.7860	-7.2607
4	1	2.28333	2.87434	.442	-3.9793	8.5460
	2	-1.52667	2.87434	.605	-7.7893	4.7360
	3	-.66333	2.87434	.821	-6.9260	5.5993
	pembanding 1	-12.10000*	2.87434	.001	-18.3627	-5.8373
	pembanding 2	-14.18667*	2.87434	.000	-20.4493	-7.9240
Pemban -ding 1	1	14.38333*	2.87434	.000	8.1207	20.6460
	2	10.57333*	2.87434	.003	4.3107	16.8360
	3	11.43667*	2.87434	.002	5.1740	17.6993
	4	12.10000*	2.87434	.001	5.8373	18.3627
	pembanding 2	-2.08667	2.87434	.482	-8.3493	4.1760
Pemban -ding 2	1	16.47000*	2.87434	.000	10.2073	22.7327
	2	12.66000*	2.87434	.001	6.3973	18.9227
	3	13.52333*	2.87434	.001	7.2607	19.7860
	4	14.18667*	2.87434	.000	7.9240	20.4493
	pembanding 1	2.08667	2.87434	.482	-4.1760	8.3493

*. The mean difference is significant at the 0.05 level.

Keterangan:

Hasil uji HSD dari keempat formula, diperoleh nilai sig. < α (0,05) sehingga Ho ditolak (*), berarti rata-rata % ED dari keempat formula dan kedua pembanding menunjukkan bahwa ada perbedaan yang signifikan antar formula, yaitu formula 1 menunjukkan perbedaan yang signifikan terhadap pembanding 1 dan pembanding 2; formula 2 menunjukkan perbedaan yang signifikan terhadap pembanding 1 dan pembanding 2; formula 3 menunjukkan perbedaan yang signifikan terhadap pembanding 1 dan pembanding 2; dan formula 4 menunjukkan perbedaan yang signifikan terhadap pembanding 1 dan pembanding 2, sedangkan formula 1 tidak menunjukkan perbedaan yang signifikan terhadap formula 2, formula 3, dan formula 4; formula 2 juga tidak menunjukkan perbedaan yang signifikan terhadap formula 3 dan formula 4; formula 3 juga tidak menunjukkan perbedaan yang signifikan terhadap formula 4.

LAMPIRAN AB

UJI F KURVA BAKU DENGAN HCl 0,1N UNTUK UJI PENETAPAN KADAR ODT DOMPERIDONE

Rep.	Konsentrasi (ppm) (x)	Absorbansi (y)	x^2	y^2	xy
I	2,012	0,097	4,0481	0,0094	0,1952
	4,024	0,140	16,1926	0,0196	0,5634
	6,036	0,203	36,4333	0,0412	1,2253
	8,048	0,253	64,7703	0,0640	2,0361
	10,06	0,313	101,2036	0,0980	3,1488
	12,072	0,372	145,7332	0,1384	4,4908
∑	14,084	0,426	198,3591	0,1815	5,9998

Persamaan Regresi pada replikasi 1 → y = 0,0277x + 0,0347

r_{hitung}/r_{tabel}: 0,9993/0,754

Rep.	Konsentrasi (ppm) (x)	Absorbansi (y)	x^2	y^2	xy
II	2,012	0,090	4,0481	0,0081	0,1811
	4,024	0,145	16,1926	0,0210	0,5835
	6,036	0,195	36,4333	0,0380	1,1770
	8,048	0,260	64,7703	0,0676	2,0925
	10,06	0,319	101,2036	0,1018	3,2091
	12,072	0,371	145,7332	0,1376	4,4787
∑	14,084	0,426	198,3591	0,1815	5,9998

Persamaan Regresi pada replikasi 1 → y = 0,0283x + 0,0306

r_{hitung}/r_{tabel}: 0,9996/0,754

Rep.	Konsentrasi (ppm) (x)	Absorbansi (y)	x^2	y^2	xy
III	2,008	0,089	4,0321	0,0079	0,1787
	4,016	0,139	16,1283	0,0193	0,5582
	6,024	0,210	36,2886	0,0441	1,2650
	8,032	0,264	64,5130	0,0697	2,1204
	10,04	0,326	100,8016	0,1063	3,2730
	12,048	0,373	145,1543	0,1391	4,4939
∑	14,056	0,426	197,5711	0,1815	5,9879

Persamaan Regresi pada replikasi 1 → y = 0,0284x + 0,0306

r_{hitung}/r_{tabel}: 0,9988/0,754

	$\sum x^2$	$\sum xy$	$\sum y^2$	n	Residual SS	RDF
Persamaan regresi 1	566,7402	17,65932	0,552056	7	0,001801	5
Persamaan regresi 2	566,7402	17,77803	0,559052	7	0,001374	5
Persamaan regresi 3	564,489	17,87722	0,567919	7	0,001752	5
Pooled regression				21	0,004927	15
Common regression	1697,969	53,31458	1,679027		0,005001	15

F_{hitung} = 0,056636

$F_{tabel\ 0,05\ (4,15)}$ = 3,06

F_{hitung} = 0,056636 < $F_{tabel\ 0,05\ (3,12)}$ = 3,06; yang berarti tidak ada perbedaan bermakna antar replikasi pada pembuatan kurva baku untuk uji penetapan kadar ODT domperidone.

LAMPIRAN AC

HASIL UJI ANAVA KEKERASAN ODT DOMPERIDONE DENGAN DESIGN EXPERT

Use your mouse to right click on individual cells for definitions.

Response 1 Kekerasan

ANOVA for selected factorial model

Analysis of variance table [Partial sum of squares - Type III]

Source	Sum of Squares	df	Mean Square	F Value	p-value Prob > F	
Model	0.33	3	0.11	1.27	0.3483	not significant
A-Ac-di-sol	*0.26*	*1*	*0.26*	*2.91*	*0.1265*	
B-PVP	*7.008E-003*	*1*	*7.008E-003*	*0.080*	*0.7846*	
AB	*0.072*	*1*	*0.072*	*0.82*	*0.3912*	
Pure Error	0.70	8	0.088			
Cor Total	1.04	11				

The "Model F-value" of 1.27 implies the model is not significant relative to the noise. There is a 34.83 % chance that a "Model F-value" this large could occur due to noise.

Values of "Prob > F" less than 0.0500 indicate model terms are significant.
In this case there are no significant model terms.
Values greater than 0.1000 indicate the model terms are not significant.
If there are many insignificant model terms (not counting those required to support hierarchy), model reduction may improve your model.

Std. Dev.	0.30	R-Squared	0.3226
Mean	2.97	Adj R-Squared	0.0686
C.V. %	9.98	Pred R-Squared	-0.5240
PRESS	1.58	Adeq Precision	2.612

A negative "Pred R-Squared" implies that the overall mean is a better predictor of your response than the current model.

"Adeq Precision" measures the signal to noise ratio. A ratio of 2.61 indicates an inadequate signal and we should not use this model to navigate the design space.

Factor	Coefficient Estimate	df	Standard Error	95% CI Low	95% CI High	VIF
Intercept	2.97	1	0.086	2.77	3.17	
A-Ac-di-sol	-0.15	1	0.086	-0.34	0.051	1.00
B-PVP	0.024	1	0.086	-0.17	0.22	1.00
AB	-0.077	1	0.086	-0.27	0.12	1.00

Final Equation in Terms of Coded Factors:

Kekerasan =
+2.97
-0.15 * A
+0.024 * B
-0.077 * A * B

Final Equation in Terms of Actual Factors:

Kekerasan =
+2.96917
-0.14583 * Ac-di-sol
+0.024167 * PVP
-0.077500 * Ac-di-sol * PVP

The Diagnostics Case Statistics Report has been moved to the Diagnostics Node.
In the Diagnostics Node, Select Case Statistics from the View Menu.

Proceed to Diagnostic Plots (the next icon in progression). Be sure to look at the:
1) Normal probability plot of the studentized residuals to check for normality of residuals.
2) Studentized residuals versus predicted values to check for constant error.
3) Externally Studentized Residuals to look for outliers, i.e., influential values.
4) Box-Cox plot for power transformations.

If all the model statistics and diagnostic plots are OK, finish up with the Model Graphs icon.

LAMPIRAN AD

HASIL UJI ANAVA KERAPUHAN ODT DOMPERIDONE DENGAN DESIGN EXPERT

Use your mouse to right click on individual cells for definitions.
Response 2 Kerapuhan
ANOVA for selected factorial model
Analysis of variance table [Partial sum of squares - Type III]

Source	Sum of Squares	df	Mean Square	F Value	p-value Prob > F	
Model	0.52	3	0.17	0.62	0.6225	not significant
A-Ac-di-sol	*0.16*	*1*	*0.16*	*0.56*	*0.4749*	
B-PVP	*0.19*	*1*	*0.19*	*0.66*	*0.4388*	
AB	*0.18*	*1*	*0.18*	*0.63*	*0.4506*	
Pure Error	2.26	8	0.28			
Cor Total	2.78	11				

The "Model F-value" of 0.62 implies the model is not significant relative to the noise. There is a 62.25 % chance that a "Model F-value" this large could occur due to noise.

Values of "Prob > F" less than 0.0500 indicate model terms are significant.
In this case there are no significant model terms.
Values greater than 0.1000 indicate the model terms are not significant.
If there are many insignificant model terms (not counting those required to support hierarchy), model reduction may improve your model.

Std. Dev.	0.53	R-Squared	0.1882
Mean	0.70	Adj R-Squared	-0.1162
C.V. %	76.10	Pred R-Squared	-0.8265
PRESS	5.08	Adeq Precision	1.608

A negative "Pred R-Squared" implies that the overall mean is a better predictor of your response than the current model.

"Adeq Precision" measures the signal to noise ratio. A ratio of 1.61 indicates an inadequate signal and we should not use this model to navigate the design space.

Factor	Coefficient Estimate	df	Standard Error	95% CI Low	95% CI High	VIF
Intercept	0.70	1	0.15	0.34	1.05	
A-Ac-di-sol	0.11	1	0.15	-0.24	0.47	1.00
B-PVP	-0.13	1	0.15	-0.48	0.23	1.00
AB	0.12	1	0.15	-0.23	0.48	1.00

Final Equation in Terms of Coded Factors:

Kerapuhan =
+0.70
+0.11 * A
-0.13 * B
+0.12 * A * B

Final Equation in Terms of Actual Factors:

Kerapuhan =
+0.69833
+0.11500 * Ac-di-sol
-0.12500 * PVP
+0.12167 * Ac-di-sol * PVP

The Diagnostics Case Statistics Report has been moved to the Diagnostics Node.
In the Diagnostics Node, Select Case Statistics from the View Menu.

Proceed to Diagnostic Plots (the next icon in progression). Be sure to look at the:
1) Normal probability plot of the studentized residuals to check for normality of residuals.
2) Studentized residuals versus predicted values to check for constant error.
3) Externally Studentized Residuals to look for outliers, i.e., influential values.
4) Box-Cox plot for power transformations.

If all the model statistics and diagnostic plots are OK, finish up with the Model Graphs icon.

LAMPIRAN AE

HASIL UJI ANAVA WAKTU HANCUR ODT DOMPERIDONE DENGAN DESIGN EXPERT

Use your mouse to right click on individual cells for definitions.
Response 3 Waktu hancur
ANOVA for selected factorial model
Analysis of variance table [Partial sum of squares - Type III]

Source	Sum of Squares	df	Mean Square	F Value	p-value Prob > F	
Model	15078.28	3	5026.09	13.93	0.0015	significant
A-Ac-di-sol	*5816.80*	*1*	*5816.80*	*16.13*	*0.0039*	
B-PVP	*7490.00*	*1*	*7490.00*	*20.77*	*0.0019*	
AB	*1771.47*	*1*	*1771.47*	*4.91*	*0.0575*	
Pure Error	2885.60	8	360.70			
Cor Total	17963.88	11				

The Model F-value of 13.93 implies the model is significant. There is only a 0.15% chance that a "Model F-Value" this large could occur due to noise.

Values of "Prob > F" less than 0.0500 indicate model terms are significant.
In this case A, B are significant model terms.
Values greater than 0.1000 indicate the model terms are not significant.
If there are many insignificant model terms (not counting those required to support hierarchy), model reduction may improve your model.

Std. Dev.	18.99	R-Squared	0.8394
Mean	67.58	Adj R-Squared	0.7791
C.V. %	28.10	Pred R-Squared	0.6386
PRESS	6492.60	Adeq Precision	8.573

The "Pred R-Squared" of 0.6386 is in reasonable agreement with the "Adj R-Squared" of 0.7791.

"Adeq Precision" measures the signal to noise ratio. A ratio greater than 4 is desirable. Your ratio of 8.573 indicates an adequate signal. This model can be used to navigate the design space.

Coefficient Factor	Standard Estimate	df	95% CI Error	95% CI Low	High	VIF
Intercept	67.58	1	5.48	54.94	80.23	
A-Ac-di-sol	-22.02	1	5.48	-34.66	-9.37	1.00
B-PVP	24.98	1	5.48	12.34	37.63	1.00
AB	-12.15	1	5.48	-24.79	0.49	1.00

Final Equation in Terms of Coded Factors:

Waktu hancur =
+67.58
-22.02 * A
+24.98 * B
-12.15 * A * B

Final Equation in Terms of Actual Factors:

Waktu hancur =
+67.58333
-22.01667 * Ac-di-sol
+24.98333 * PVP
-12.15000 * Ac-di-sol * PVP

The Diagnostics Case Statistics Report has been moved to the Diagnostics Node.
In the Diagnostics Node, Select Case Statistics from the View Menu.

Proceed to Diagnostic Plots (the next icon in progression). Be sure to look at the:
1) Normal probability plot of the studentized residuals to check for normality of residuals.
2) Studentized residuals versus predicted values to check for constant error.
3) Externally Studentized Residuals to look for outliers, i.e., influential values.
4) Box-Cox plot for power transformations.

If all the model statistics and diagnostic plots are OK, finish up with the Model Graphs icon.

LAMPIRAN AF

HASIL UJI ANAVA WAKTU PEMBASAHAN ODT DOMPERIDONE DENGAN DESIGN EXPERT

Use your mouse to right click on individual cells for definitions.
Response 4 Waktu pembasahan
ANOVA for selected factorial model
Analysis of variance table [Partial sum of squares - Type III]

Source	Sum of Squares	df	Mean Square	F Value	p-value Prob > F	
Model	10035.21	3	3345.07	5.11	0.0290	significant
A-Ac-di-sol	*5940.75*	*1*	*5940.75*	*9.08*	*0.0167*	
B-PVP	*3971.97*	*1*	*3971.97*	*6.07*	*0.0391*	
AB	*122.50*	*1*	*122.50*	*0.19*	*0.6767*	
Pure Error	5236.39	8	654.55			
Cor Total	15271.61	11				

The Model F-value of 5.11 implies the model is significant. There is only a 2.90% chance that a "Model F-Value" this large could occur due to noise.

Values of "Prob > F" less than 0.0500 indicate model terms are significant.
In this case A, B are significant model terms.
Values greater than 0.1000 indicate the model terms are not significant.
If there are many insignificant model terms (not counting those required to support hierarchy), model reduction may improve your model.

Std. Dev.	25.58	R-Squared	0.6571
Mean	72.36	Adj R-Squared	0.5285
C.V. %	35.36	Pred R-Squared	0.2285
PRESS	11781.89	Adeq Precision	5.476

The "Pred R-Squared" of 0.2285 is not as close to the "Adj R-Squared" of 0.5285 as one might normally expect. This may indicate a large block effect or a possible problem with your model and/or data. Things to consider are model reduction, response transformation, outliers, etc.

"Adeq Precision" measures the signal to noise ratio. A ratio greater than 4 is desirable. Your ratio of 5.476 indicates an adequate signal. This model can be used to navigate the design space.

Factor	Coefficient Estimate	df	Standard Error	95% CI Low	95% CI High	VIF
Intercept	72.36	1	7.39	55.33	89.39	
A-Ac-di-sol	22.25	1	7.39	5.22	39.28	1.00
B-PVP	18.19	1	7.39	1.16	35.22	1.00
AB	3.20	1	7.39	-13.84	20.23	1.00

Final Equation in Terms of Coded Factors:

Waktu pembasahan =
+72.36
+22.25 * A
+18.19 * B
+3.20 * A * B

Final Equation in Terms of Actual Factors:

Waktu pembasahan =
+72.36167
+22.25000 * Ac-di-sol
+18.19333 * PVP
+3.19500 * Ac-di-sol * PVP

The Diagnostics Case Statistics Report has been moved to the Diagnostics Node.
In the Diagnostics Node, Select Case Statistics from the View Menu.

Proceed to Diagnostic Plots (the next icon in progression). Be sure to look at the:
1) Normal probability plot of the studentized residuals to check for normality of residuals.
2) Studentized residuals versus predicted values to check for constant error.
3) Externally Studentized Residuals to look for outliers, i.e., influential values.
4) Box-Cox plot for power transformations.

If all the model statistics and diagnostic plots are OK, finish up with the Model Graphs icon.

LAMPIRAN AG

HASIL UJI ANAVA RASIO ABSORPSI AIR ODT DOMPERIDONE DENGAN DESIGN EXPERT

Use your mouse to right click on individual cells for definitions.
Response 5 Rasio absorpsi air
ANOVA for selected factorial model
Analysis of variance table [Partial sum of squares - Type III]

Source	Sum of Squares	df	Mean Square	F Value	p-value Prob > F	
Model	1665.95	3	555.32	14.00	0.0015	significant
A-Ac-di-sol	*1592.76*	*1*	*1592.76*	*40.15*	*0.0002*	
B-PVP	*69.17*	*1*	*69.17*	*1.74*	*0.2232*	
AB	*4.03*	*1*	*4.03*	*0.10*	*0.7582*	
Pure Error	317.37	8	39.67			
Cor Total	1983.32	11				

The Model F-value of 14.00 implies the model is significant. There is only a 0.15% chance that a "Model F-Value" this large could occur due to noise.

Values of "Prob > F" less than 0.0500 indicate model terms are significant.
In this case A are significant model terms.
Values greater than 0.1000 indicate the model terms are not significant.
If there are many insignificant model terms (not counting those required to support hierarchy), model reduction may improve your model.

Std. Dev.	6.30	R-Squared	0.8400
Mean	42.19	Adj R-Squared	0.7800
C.V. %	14.93	Pred R-Squared	0.6400
PRESS	714.08	Adeq Precision	7.657

The "Pred R-Squared" of 0.6400 is in reasonable agreement with the "Adj R-Squared" of 0.7800.

"Adeq Precision" measures the signal to noise ratio. A ratio greater than 4 is desirable. Your ratio of 7.657 indicates an adequate signal. This model can be used to navigate the design space.

Factor	Coefficient Estimate	df	Standard Error	95% CI Low	95% CI High	VIF
Intercept	42.19	1	1.82	38.00	46.39	
A-Ac-di-sol	11.52	1	1.82	7.33	15.71	1.00
B-PVP	-2.40	1	1.82	-6.59	1.79	1.00
AB	-0.58	1	1.82	-4.77	3.61	1.00

Final Equation in Terms of Coded Factors:

Rasio absorpsi air =
+42.19
+11.52 * A
-2.40 * B
-0.58 * A * B

Final Equation in Terms of Actual Factors:

Rasio absorpsi air =
+42.19250
+11.52083 * Ac-di-sol
-2.40083 * PVP
-0.57917 * Ac-di-sol * PVP

The Diagnostics Case Statistics Report has been moved to the Diagnostics Node.
In the Diagnostics Node, Select Case Statistics from the View Menu.

Proceed to Diagnostic Plots (the next icon in progression). Be sure to look at the:
1) Normal probability plot of the studentized residuals to check for normality of residuals.
2) Studentized residuals versus predicted values to check for constant error.
3) Externally Studentized Residuals to look for outliers, i.e., influential values.
4) Box-Cox plot for power transformations.

If all the model statistics and diagnostic plots are OK, finish up with the Model Graphs icon.

LAMPIRAN AH

HASIL UJI ANAVA %ED ODT DOMPERIDONE DENGAN DESIGN EXPERT

Use your mouse to right click on individual cells for definitions.
Response 6 %ED
ANOVA for selected factorial model
Analysis of variance table [Partial sum of squares - Type III]

Source	Sum of Squares	df	Mean Square	F Value	p-value Prob > F	
Model	23.95	3	7.98	0.46	0.7167	not significant
A-Ac-di-sol	*7.43*	*1*	*7.43*	*0.43*	*0.5306*	
B-PVP	*1.51*	*1*	*1.51*	*0.087*	*0.7749*	
AB	*15.01*	*1*	*15.01*	*0.87*	*0.3787*	
Pure Error	138.30	8	17.29			
Cor Total	162.25	11				

The "Model F-value" of 0.46 implies the model is not significant relative to the noise. There is a 71.67 % chance that a "Model F-value" this large could occur due to noise.

Values of "Prob > F" less than 0.0500 indicate model terms are significant.
In this case there are no significant model terms.
Values greater than 0.1000 indicate the model terms are not significant.
If there are many insignificant model terms (not counting those required to support hierarchy), model reduction may improve your model.

Std. Dev.	4.16	R-Squared	0.1476
Mean	79.32	Adj R-Squared	-0.1721
C.V. %	5.24	Pred R-Squared	-0.9179
PRESS	311.18	Adeq Precision	1.587

A negative "Pred R-Squared" implies that the overall mean is a better predictor of your response than the current model.

"Adeq Precision" measures the signal to noise ratio. A ratio of 1.59 indicates an inadequate signal and we should not use this model to navigate the design space.

Factor	Coefficient Estimate	df	Standard Error	95% CI Low	95% CI High	VIF
Intercept	79.32	1	1.20	76.56	82.09	
A-Ac-di-sol	0.79	1	1.20	-1.98	3.55	1.00
B-PVP	0.35	1	1.20	-2.41	3.12	1.00
AB	-1.12	1	1.20	-3.89	1.65	1.00

Final Equation in Terms of Coded Factors:

%ED =
+79.32
+0.79 * A
+0.35 * B
-1.12 * A * B

Final Equation in Terms of Actual Factors:

%ED =
+79.32333
+0.78667 * Ac-di-sol
+0.35500 * PVP
-1.11833 * Ac-di-sol * PVP

The Diagnostics Case Statistics Report has been moved to the Diagnostics Node.
In the Diagnostics Node, Select Case Statistics from the View Menu.

Proceed to Diagnostic Plots (the next icon in progression). Be sure to look at the:
1) Normal probability plot of the studentized residuals to check for normality of residuals.
2) Studentized residuals versus predicted values to check for constant error.
3) Externally Studentized Residuals to look for outliers, i.e., influential values.
4) Box-Cox plot for power transformations.

If all the model statistics and diagnostic plots are OK, finish up with the Model Graphs icon.

LAMPIRAN AI

HASIL UJI STATISTIK HASIL PERCOBAAN DAN HASIL TEORITIS PADA UJI KEKERASAN ODT DOMPERIDONE

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Hasil Percobaan Kekerasan	2.9700	4	.19339	.09670
	Hasil Teoritis Kekerasan	2.9700	4	.19579	.09789

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	Hasil Percobaan Kekerasan & Hasil Teoritis Kekerasan	4	.999	.001

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
					Lower	Upper			
Pair 1	Hasil Percobaan Kekerasan - Hasil Teoritis Kekerasan	.00000	.00816	.00408	-.01299	.01299	.000	3	1.000

Hipotesa Pengujian :

Ho diterima jika T_{hitung} (0,000) < $T_{0,025\ (3)}$ (3,182), berarti hasil percobaan dan hasil teoritis pada uji kekerasan tidak berbeda bermakna antar formula.

LAMPIRAN AJ

HASIL UJI STATISTIK HASIL PERCOBAAN DAN HASIL TEORITIS PADA UJI KERAPUHAN ODT DOMPERIDONE

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Hasil Percobaan Kerapuhan	.7000	4	.24014	.12007
	Hasil Teoritis Kerapuhan	.7000	4	.24055	.12028

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	Hasil Percobaan Kerapuhan & Hasil Teoritis Kerapuhan	4	.999	.001

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
					Lower	Upper			
Pair 1	Hasil Percobaan Kerapuhan - Hasil Teoritis Kerapuhan	.00000	.00816	.00408	-.01299	.01299	.000	3	1.000

Hipotesa Pengujian :

Ho diterima jika T_{hitung} (0,000) < $T_{0,025\ (3)}$ (3,182), berarti hasil percobaan dan hasil teoritis pada uji kerapuhan tidak berbeda bermakna antar formula.

LAMPIRAN AK

HASIL UJI STATISTIK HASIL PERCOBAAN DAN HASIL TEORITIS PADA UJI WAKTU HANCUR ODT DOMPERIDONE

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Hasil Percobaan Waktu Hancur	67.5825	4	40.93014	20.46507
	Hasil Teoritis Waktu Hancur	67.5800	4	40.92372	20.46186

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	Hasil Percobaan Waktu Hancur & Hasil Teoritis Waktu Hancur	4	1.000	.000

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
					Lower	Upper			
Pair 1	Hasil Percobaan Waktu Hancur - Hasil Teoritis Waktu Hancur	.00250	.00957	.00479	-.01273	.01773	.522	3	.638

Hipotesa Pengujian :

Ho diterima jika T_{hitung} (0,522) < $T_{0,025\ (3)}$ (3,182), berarti hasil percobaan dan hasil teoritis pada uji waktu hancur tidak berbeda bermakna antar formula.

LAMPIRAN AL

HASIL UJI STATISTIK HASIL PERCOBAAN DAN HASIL TEORITIS PADA UJI WAKTU PEMBASAHAN ODT DOMPERIDONE

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Hasil Percobaan Waktu Pembasahan	72.3600	4	33.39318	16.69659
	Hasil Teoritis Waktu Pembasahan	72.3600	4	33.39019	16.69510

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	Hasil Percobaan Waktu Pembasahan & Hasil Teoritis Waktu Pembasahan	4	1.000	.000

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
					Lower	Upper			
Pair 1	Hasil Percobaan Waktu Pembasahan - Hasil Teoritis Waktu Pembasahan	.00000	.00816	.00408	-.01299	.01299	.000	3	1.000

Hipotesa Pengujian :

Ho diterima jika T_{hitung} (0,000) < $T_{0,025\ (3)}$ (3,182), berarti hasil percobaan dan hasil teoritis pada uji waktu pembasahan tidak berbeda bermakna antar formula.

LAMPIRAN AM

HASIL UJI STATISTIK HASIL PERCOBAAN DAN HASIL TEORITIS PADA UJI RASIO ABSORPSI AIR ODT DOMPERIDONE

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Hasil Percobaan Rasio Absorpsi Air	42.1900[a]	4	13.60425	6.80213
	Hasil Teoritis Rasio Absorpsi Air	42.1900[a]	4	13.60425	6.80213

a. The correlation and t cannot be computed because the standard error of the difference is 0.

Hipotesa Pengujian :

Ho diterima jika T_{hitung} (0,000) < $T_{0,025\ (3)}$ (3,182), berarti hasil percobaan dan hasil teoritis pada uji rasio absorpsi air tidak berbeda bermakna antar formula.

LAMPIRAN AN

HASIL UJI STATISTIK HASIL PERCOBAAN DAN HASIL TEORITIS PADA UJI %ED ODT DOMPERIDONE

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Hasil Percobaan %ED	79.7200	4	.95202	.47601
	Hasil teoritis %ED	79.3200	4	1.63340	.81670

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	Hasil Percobaan %ED & Hasil teoritis %ED	4	.947	.053

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
					Lower	Upper			
Pair 1	Hasil Percobaan %ED - Hasil teoritis %ED	.4000	.79335	.39667	-.8624	1.66239	1.008	3	.388

Hipotesa Pengujian :

Ho diterima jika T_{hitung} (0,000) < $T_{0,025\ (3)}$ (3,182), berarti hasil percobaan dan hasil teoritis pada uji %ED tidak berbeda bermakna antar formula.

LAMPIRAN AO

HASIL UJI STATISTIK SEBELUM DAN SETELAH 1 BULAN PADA UJI STABILITAS WAKTU HANCUR ODT DOMPERIDONE

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Waktu Hancur	67.5825	4	40.93014	20.46507
	Waktu Hancur Uji Stabilitas	53.2000	4	30.68621	15.34310

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	Waktu Hancur & Waktu Hancur Uji Stabilitas	4	.983	.017

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
					Lower	Upper			
Pair 1	Waktu Hancur - Waktu Hancur Uji Stabilitas	14.38250	12.10176	6.05088	-4.87409	33.63909	2.377	3	.098

Hipotesa Pengujian :

Ho diterima jika T_{hitung} (2,377) < $T_{0,025\ (3)}$ (3,182), berarti hasil uji statistik sebelum dan setelah 1 bulan pada uji waktu hancur tidak berbeda bermakna antar formula.

LAMPIRAN AP

HASIL UJI STATISTIK SEBELUM DAN SETELAH 1 BULAN PADA UJI STABILITAS WAKTU PEMBASAHAN ODT DOMPERIDONE

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Waktu_Pembasahan	72.3600	4	33.39318	16.69659
	Waktu_Pembasahan_Uji_Stabilitas	68.3600	4	33.41716	16.70858

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	Waktu_Pembasahan & Waktu_Pembasahan_Uji_Stabilitas	4	.927	.073

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
					Lower	Upper			
Pair 1	Waktu_Pembasah-an _ Waktu_ Pembasah-an_ Uji_ Stabilitas	4.00000	12.74938	6.37469	-16.2871	24.28710	.627	3	.575

Hipotesa Pengujian :

Ho diterima jika T_{hitung} (0,627) < $T_{0,025\ (3)}$ (3,182), berarti hasil uji statistik sebelum dan setelah 1 bulan pada uji waktu pembasahan tidak berbeda bermakna antar formula.